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ABSTRACT OF THE DISSERTATION
T Cell Immunity in Pancreatic Cancer is Undermined by Dendritic Cell Dysfunction
by
Samarth Hegde
Doctor of Philosophy in Biology and Biomedical Sciences
Molecular Cell Biology
Washington University in St. Louis, 2019
Professor David G. DeNardo, Chair

Pancreatic cancer carries a dismal prognosis, and desperately needs viable
therapeutic interventions beyond chemo-radiation. T cell-dependent immunotherapies
have shown great promise in several tumor types, but have not been effective for the
vast majority of pancreatic cancer patients. This is, in part, due to our limited
understanding of how antigenicity of pancreatic lesions is recognized, and how adaptive
immunity is overcome in this disease. We sought to study tumor-immune interactions
and identify mechanisms for this immune-failure using several spontaneous and
unperturbed mouse models of pancreatic adenocarcinoma. We found that early
pancreatic lesions fail to elicit tumor-limiting CD4+ TH1 and CD8+ T cell activity against a
neoantigen,

even

though

there

is

antigen

recognition.

Instead,

the

unique

fibroinflammatory microenvironment favors the expansion of CD4+ TH17 T cells that are

x

tumor-promoting. This is in contrast to similarly modeled lung adenocarcinoma; wherein
early antigen-recognition is followed by favorable anti-tumor responses.
We report that endogenous antigen-specific immunity in the pancreas is aberrant
partly due to a scarcity of innate cells called conventional dendritic cells (cDCs).
Restoring cDCs pharmacologically at an early stage in pancreatic tumorigenesis can
rescue CD8+ T cell activity and limit tumor-promoting TH17 inflammation. Additionally,
therapies targeting cDC infiltration and function in advanced pancreatic cancer can
indirectly enhance CD8+ T cell and CD4+ TH1 activity to help control disease
progression. Importantly, cDC-targeted therapy in established disease results in
increased responsiveness to radiation therapy and immunotherapy in a T celldependent manner. These findings expand our understanding of T cell ineffectiveness
in pancreatic cancer, clarifying why targeting T cells alone is insufficient in this disease
context. Additionally, the results underscore the value of combinatorial strategies
modulating cDCs to benefit existing therapies in pancreatic cancer and similar solid
malignancies.
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Chapter 1: Introduction
Cancer develops in close communication and interaction with the host, and the
immune system is an integral player in this interplay. The outcome of this interaction
between transformed cells and the surrounding immune system can be varied,
depending on numerous factors such as the tissue microenvironment and inflammation.
This close crosstalk between cancer and immune cells is no more apparent than in
pancreatic cancer, which is notorious for its highly inflamed microenvironment and
enrichment of stromal (non-tumor) cells.
The broad goal of my dissertation was to understand how pancreatic cancer
evades host T cell immunity, and target this vulnerability to help boost immune
responses in this disease. First, I will illustrate how tumor-specific antigens are
recognized and acted upon by host immunity in a spontaneous model of pancreatic
cancer, and how this tumor environment contrasts from other similar tumors. Second, I
will demonstrate how the dearth of a rare antigen-presenting cell type in pancreatic
tumors can dictate anti-tumor immunity and tumor progression. Finally, I will describe
how this cell type might be targeted pharmacologically to boost existing T cell immunity
in pancreatic cancer and augment current treatment strategies such as radiation
therapy and immunotherapy. This introductory chapter will review pancreatic cancer,
our knowledge of its immune contexture, and the gaps in our understanding of antitumor immunity in this disease.

1

1.1 Pancreatic cancer
Pancreatic cancer is a lethal malignancy. Pancreatic ductal adenocarcinoma (or
PDAC) is the most common form of pancreatic cancer and carries the most dismal
prognosis, with a 5-year survival rate of less than 9%. It is a relatively rare cancer
(3.2% of all new cancer cases), but currently the 4th leading cause of cancer deaths in
the US encompassing 8% of all cancer deaths (Siegel et al., 2019). Patients present at
advanced stages due to the fact that PDAC progresses rapidly with very few symptoms
and metastasizes aggressively. Only a minority of patients (~10%) are eligible for
surgical resections, and current therapies for unresectable/metastatic cases include
standard-of-care chemotherapy such as Gemcitabine-Abraxane or FOLFIRINOX
extending median survival modestly (Neoptolemos et al., 2018). Radiation therapy has
also been utilized usually in neoadjuvant or adjuvant setting to achieve tumor control
when chemotherapy fails (Schmidt et al., 2012). PDAC is notoriously unresponsive to
treatment modalities (Aglietta et al., 2014; O'Reilly et al., 2019; Royal et al., 2010), and
patients are in need of new approaches that can result in more tangible and durable
responses. To develop better therapies for PDAC, one must understand the etiology
and unique characteristics of this disease.
PDAC predominantly develops from three kinds of precursor lesions–
intraepithelial neoplasia (PanINs), intraductal papillary mucinous neoplasms, and
mucinous cystic neoplasms. PanINs are the predominant steps observed clinically in
PDAC progression, and develop over 15~20 years on average (Figure 1.1). Certain
factors raise a person’s risk of developing PDAC; these include but are not limited to
inflammation caused by obesity, alcohol, smoking, diabetes, and idiopathic pancreatitis
2

(Hidalgo et al., 2015), in addition to certain familial history. PDAC progression is driven
by some core oncogenic pathways. These include aberrant Hedgehog signaling, NFK-b
signaling, and p53- or p16-dependent signaling, but the predominant alteration is
oncogenic Ras signaling (Bailey et al., 2016b; Jones et al., 2008). Oncogenic KRAS is
necessary for PDAC initiation and present in >90% of patients, with other prominent
mutations including CDKN2A, TP53 and SMAD4 inactivation. However, compared to
other tumors such as melanoma, cutaneous squamous carcinomas, and lung
adenocarcinomas, PDAC has a low mutational burden (Yarchoan et al., 2017a). PDAC
is

also

notorious

for

its

extremely

fibrotic,

hypoxic,

and

nutrient-deprived

microenvironment having substantial immune infiltration. This complex stroma plays a
major role in its pathogenesis and has been shown to make drug delivery and cytolytic
activity difficult (Kieler et al., 2018). To understand how an immunodominant stroma can
dictate PDAC outcomes, one must first review the interplay between host immunity and
cancer during immune surveillance.

1.2 Cancer immune surveillance
It has been known for close to a century that the immune system has an
adversarial role in tumor progression. This concept emerged in the late 19th century
and beginning of the 20th century, describing how immune system might be geared for
attacking ‘foreign’ malignancies. Notable findings by William Coley and Paul Ehrlich,
amongst others, proposed tumor development could be opposed by manipulating the
patients’ immune response; Burnet and Thomas formally structured this as the cancer
immunosurveillance hypothesis (Burnet, 1957). Seminal studies in the early 1990s and
2000s demonstrated that both innate and adaptive immune compartments participate in
3

surveying the host to eliminate aberrant/mutated cells, and can shape or mold extant
disease (Dunn et al., 2002). According to this theory, clinically apparent tumors have
somehow managed to avoid detection by various arms of the immune system. There is
clear clinical evidence for this phenomenon, demonstrated by the increased incidence
of cancer in immune-deficient patients and organ transplant recipients on immune
suppressors (Salavoura et al., 2008). The whole field of ‘cancer immunotherapy’ is
based on this concept, designed to unleash the host immune system in different ways to
better recognize tumors and help control their initiation and growth.
Even though our immune system is evolutionarily wired to oppose neoplastic
growth, the complex interactions in the tumor environment can rewire and co-opt the
response to be ineffective or tumor-promoting. Virchow hypothesized a century ago that
chronic inflammation can promote cell proliferation, and Dvorak described tumors as
wounds that “never heal”. This has been borne out in observations that chronic
inflammatory conditions (colitis, Crohn’s disease, hepatitis, pancreatitis) and acute
irritants/agents (silica, asbestos, smoke) are known risk factors for tumor development
(Balkwill and Mantovani, 2001). It has also been documented that certain immune
infiltrates such as tumoral neutrophils and myeloid suppressor cells correlate with poor
outcomes in most cancer patients (Templeton et al., 2014). Thus, there exists a
constant battle between the host immune system and incipient tumors, with each
compartment influencing and shaping the other and tumors ultimately arising due to cooption of immune responses. The immune surveillance hypothesis has now crystallized
into the broader term “cancer immunoediting” to take into account this bidirectional
interaction and sculpting (Schreiber et al., 2011). There are numerous players involved
4

in this host immune response discussed elsewhere (Binnewies et al., 2018; Chen and
Mellman, 2013; Salmon et al., 2019); I will highlight a few cell types relevant to my
project below.

1.3 Adaptive T cell immunity in cancer
T cells are the predominant arm of host adaptive immune responses against
cancer, and carry out specific and restricted functions to eliminate tumor cells. CD8+ T
cells are primary cytolytic effector cells in tumor resolution, although other cell types
such as CD4+ T cell subsets, NK and NKT cells can also exert cytotoxicity in certain
contexts. CD4+ T cells have more diverse functions, chiefly involving cytokine
production to regulate either activation or suppression of CD8+ T cell function. The
specificity of this response is cultivated against antigens derived from cancer cells.
These antigens can be either tumor-specific or tumor-associated, and are presented on
major histocompatibility complex (MHC) to T cells with cognate T cell receptors (TCR).
Tumor-specific antigens, also termed ‘neoantigens’ due to their foreign-ness, are often
aberrant peptides arising from non-synonymous mutations and other genetic alterations,
while tumor-associated antigens are over-expressed in malignant cells but also present
in normal cells or spatio-temporally restricted cell lineages (Yarchoan et al., 2017b). The
recognition of these antigens depends on their ‘immunogenicity’ and is critical to
successful T cell activation and subsequent T cell-dependent tumor clearance (Figure
1.2). T cell activation occurs through antigen presentation by specialized antigenpresenting cells (APCs), chiefly dendritic cells, with appropriate co-stimulation.
Productive T cell activation is accompanied by rapid proliferation and metabolic
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changes to expand this antigen-specific pool, boosting the likelihood of direct
tumoricidal control.
Unlike the narrowly-defined evolutionary role of CD8+ T cells, CD4+ T cells
differentiate into a wide variety of subtypes based on how and by whom they are
stimulated. CD4+ T cells can be classified into five broad subtypes– TH1, TH2, TH17,
TREG, and TFH. These subtypes have compartmentalized roles, different cytokine
expression and transcriptional networks in homeostasis, defense response, and selftolerance (Zhu et al., 2010). They are especially plastic and heterogenous in
inflammatory contexts such as in cancer. TH1 CD4+ T cells are canonical anti-tumor
helper cells, and can ‘help’ cognate antigen-specific CD8+ T cell activity by ‘licensing’
APCs through signaling molecules such as CD40 ligand, or providing cytokines such as
IL-2 directly to CD8+ T cells (Summers deLuca and Gommerman, 2012) (Figure 1.3).
TH2 cells favor a more long-term humoral response and produce cytokines that are
implicated in wound-healing and suppression of inflammation in the tumor
microenvironment. Both TH1 and TH2 subtypes can enhance anti-tumor immunity in
differing ways, but TH2 cells have been mostly associated with aberrant inflammatory
pathology and cancer progression (Tan and Coussens, 2007). TREG are regulatory cells,
either induced or conventionally produced, to maintain self-tolerance and modulate the
strength of immune responses by suppressing cytokine production by other CD4+ TH or
CD8+ T cells. The TH17 subtype is one of the more nebulous cells in the cancer
microenvironment; it has well-defined inflammatory roles in autoimmunity but
incongruent associations when it comes to tumor immunity. Recent work has shown
these cell types are highly sensitive to the microenvironment and stimuli, resulting in
6

beneficial, but more often pathologic cytokine production (Bailey et al., 2014). In
summary, a wide gamut of CD4+ T cells can dictate anti-tumor immunity fate, and they
often become tumor-permissive given environmental cues.
A hallmark of all tumors is their diverse mechanisms of evading immune control.
Focusing on solid tumors, T cells are often subdued by four broad mechanisms – 1)
inhibitory checkpoints, 2) aberrant recruitment, 3) active exclusion, and 4) metabolic
toxicity (Anderson et al., 2017). Inhibitory checkpoint receptors such as PD-1, CTLA-4,
TIM-3 and LAG-3 are ‘molecular brakes’ expressed on T cells in response to antigenspecific activation, and serve as evolutionary mechanisms of tolerance to prevent
indiscriminate tissue damage during infections and limit autoimmunity. Tumors co-opt
this safeguarding mechanism to evade immunity by either directly expressing ligands
(such as PD-L1) or by encouraging the expression of cognate ligands on APCs or
stromal cell in the tumor environment (PD-L2 or soluble ligands such as HMGB1 or
galectin-9). Thus, CD8+ and CD4+ T cells countering a tumor frequently become
unresponsive to antigen– termed ‘anergy’, and subsequently non-functional due to
transcriptional and epigenetic alterations– termed ‘exhaustion’ (Philip and Schietinger,
2019). Indeed, a major clinical opportunity has been reversing this pathway to ‘unleash’
T cell brakes and ‘uncloak’ tumor cells; the most notable being anti-PD-1, anti-PD-L1
and anti-CTLA-4 therapies that have seen astounding and demonstrable success in
melanoma, lung cancer and subsets of breast and colon cancer patients (Ribas and
Wolchok, 2018).
Distinct from inhibitory checkpoint ligation in the tumor microenvironment or
periphery, T cells are often also prevented from trafficking to the tumor and/or excluded
7

from tumor parenchyma by tumor-derived or tumor-associated stromal factors – notably
TGFβ, IL-10 and VEGF. It has been shown that T cell chemoattractants are
downregulated in certain tumors to hinder their recruitment (Spranger et al., 2015).
Cancer-associated fibroblasts producing CXCL12 have been shown to physically
exclude T cells from the tumor (Feig et al., 2013). Abnormal tumor vasculature and
hypoxia have also been demonstrated to trap T cells, induce T cell apoptosis and/or
limit their proliferation in situ (Chouaib et al., 2012). Lastly, preferential recruitment of
immunosuppressive cells such as myeloid-derived suppressor cells, tumor-associated
macrophages and tumor-associated granulocytes by chemokines such as CCL2, CSF1,
CXCL1 and CXCL2 also indirectly limits T cell function (DeNardo and Ruffell, 2019).
Even if T cells surmount these barriers, certain tumor-intrinsic changes can
render them oblivious. In preclinical models and correlative clinical studies, tumors have
been shown to lose their prominent antigen-expressing clones via mutations or DNA
methylation precipitated by immune selection (Angelova et al., 2018; Rosenthal et al.,
2019). Alternatively, tumors have been demonstrated to distort their antigenpresentation machinery by downregulation of surface MHC, or mutations in
β2m/immunoproteasome components to essentially become invisible to MHCdependent CD8+ T cells (Paulson et al., 2014; Sade-Feldman et al., 2017). In summary,
multiple non-redundant pathways have evolved to render T cells ineffective in solid
tumors, and the pressing question is to identify what pathways are targetable in which
tumor type. Of note, many of these mechanisms of CD8+ T cell evasion impinge upon
cells necessary for their initial priming, namely dendritic cells (DCs).

8

1.4 Dendritic cells in cancer
DCs are a critical bridge between the innate and the adaptive immune system
and often the sentinels of immunity against pathogens and immune-tolerance (Merad et
al., 2013). DCs engulf cellular debris similar to other myeloid scavengers such as
macrophages and monocytes, but are specialized to use this information to promote T
cell distinctive responses (Schlitzer et al., 2015a). The canonical mechanism involves
cellular debris uptake by DCs and proteasomal processing to present antigen peptide in
the context of MHC-II to surveying CD4+ T cells that in turn promote/regulate CD8+ T
cell activity. At steady state, DCs survey tissue in ‘immature’ form, being highly
phagocytic and sampling both self and mutated peptides. Tumor surveillance also relies
on an important mechanism termed ‘cross-presentation’; this involves certain DCs
taking up exogenous antigen upon immunogenic cell death and processing it to directly
present on MHC-I to cognate CD8+ T cells. Another means of T cell education involves
‘cross-dressing’ wherein exogenous peptide-MHC complex is handed off via membrane
transfer to be presented to CD8+ T cells by another DC (Li et al., 2012). A key
characteristic of DCs is their migratory capacity, which enables them to traffic antigen
from a tumor to its draining lymphoid organ and prime naïve T cells to exponentially
expand an activated pool and stimulate more systemic anti-tumor responses (Broz et
al., 2014; Headley et al., 2016; Roberts et al., 2016).
Specifically, in the context of solid tumors, the magnitude and persistence of a T
cell response against tumor is dependent on the initial priming by conventional DCs
(cDCs), which is the cell type I will focus on here. cDCs are derived from the common
dendritic cell progenitors (CDPs) in bone marrow and have been broadly categorized as
9

either cDC1s or cDC2s (Satpathy et al., 2012b; See et al., 2017). cDC1s, marked by
CD141 in humans and by CD24, CD103 (migratory) and CD8a (lymphoid) in mice, are
responsible for CD8+ cytotoxic T lymphocyte cross-presentation (Guilliams et al., 2016;
Haniffa et al., 2012). cDC1 development is dependent on transcription factors such as
basic leucine zipper transcription factor ATF-like 3 (Batf3), inhibitor of DNA binding 2
(Id2) and interferon regulatory factor 8 (Irf8)(Becker et al., 2012; Ginhoux et al., 2009;
Hildner et al., 2008). Irf8 is essential to cDC1 identity as it drives a maturation and
antigen presentation program to enhance their co-stimulatory capacity and antigenpresentation machinery (Lee et al., 2017; Paul et al., 2015; Schlitzer et al., 2015b).
cDC2s, on the other hand, are marked by CD1c in humans and by CD11b, CD172a
(migratory) and CD4 (lymphoid) in mice (Guilliams et al., 2016). cDC2 progenitors
downregulate Irf8 to promote an Irf4-dependent developmental program, and cDC2s
predominantly stimulate CD4+ T cells to shape their identity and function. cDC2s have
been implicated in helper CD4+ T cell (TH) priming (Gardner and Ruffell, 2016) but also
shown to be involved in generating tolerogenic and regulatory CD4+ T cells (Binnewies
et al., 2019; Gao et al., 2013; Krishnaswamy et al., 2017; Laoui et al., 2016).
In addition to canonical antigen-presentation, cDCs have been implicated in other
aspects of T cell biology crucial to anti-tumor immunity. cDC1s are known to secrete
chemoattractants such as CXCL9 and CXCL10 to help recruit activated T cells to sites
of inflammation (Spranger et al., 2017). Loss of cDC1s is associated with a concomitant
loss of memory T cell responses, indicating their importance to T cell homing and reeducation (Alexandre et al., 2016; Spranger et al., 2017). Lastly, cDC1s have been
shown to produce cytokines such as IL-12, IL-15 and IL-1a to enhance and license T
10

cell, NK cell and NKT cell cytotoxicity (Broz et al., 2014; Garris et al., 2018; Mattei et al.,
2001; Ruffell et al., 2014; Sanchez-Paulete et al., 2016). It is hence unsurprising that
cDCs are required to restrain tumor growth in a T cell-dependent manner and Batf3dependent

DCs

are

critical

to

the

success

of

CD8+

T

cell-mediated

chemo/radiation/immunotherapies (Binnewies et al., 2019; Byrne and Vonderheide,
2016; de Mingo Pulido et al., 2018; Hammerich et al., 2019b; Roberts et al., 2016;
Rodriguez-Ruiz et al., 2016; Salmon et al., 2016; Spranger et al., 2017). In patients,
intratumoral CD141+ cDC1 prevalence, BDCA-1+ cDC2 density, and circulating cDC
progenitor presence correlates with better outcomes and immunotherapy response in
many types of solid tumors such as melanoma, squamous cancer, breast cancer, and
lung cancer (Barry et al., 2018; Binnewies et al., 2019; Michea et al., 2018; Pfirschke et
al., 2016; Spranger et al., 2015; Zilionis et al., 2019) suggesting a positive prognostic
significance to their presence in the tumor microenvironment and periphery.
Tumor immune escape hence often involves dysfunction in DC biology. The
tumor microenvironment can induce anergy by prompting immature DCs (those not
having antigen-presentation/priming capacity) to become tolerogenic, thus preventing
anti-tumor activation of T cells (Clement et al., 2014). Tumors can also suppress
productive DC-T cell interactions through cytokines such as IL-10 (Ruffell et al., 2014),
IL-6 (Tang et al., 2015) and COX/PGE2 (Zelenay et al., 2015). The tumor
microenvironment is also brimming with immunosuppressive myeloid cells; these cells
are inefficient antigen processors and can outcompete rarer cDCs for antigen sampling
precluding anti-tumor T cell activation. Additionally, physical or chemokine constraints in
the tumor microenvironment can limit the migratory capacity of tumoral cDCs, which can
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prevent them from priming in the draining lymph node. Lastly, tumors can exert DC
suppression distally, by influencing DC differentiation in bone marrow. cDCs are
replenished systemically as they turn over quickly in non-lymphoid tissue (Durai and
Murphy, 2016; Liu et al., 2007); their differentiation from precursors in the bone marrow
is primarily driven by fms-like tyrosine kinase 3 ligand (Flt3L) (McKenna et al., 2000;
Waskow et al., 2008). Tumor-derived factors such as granulocyte-colony stimulating
factor (G-CSF) can enhance granulocytic and monocytic expansion in tumors at the
expense of DC differentiation as another means of immune escape (Meyer et al., 2018).
In summary, cDCs are important mediators of antitumor immunity and their
absence can severely limit CD8+ T and TH cell responses in mice and humans. It has
become extremely important to understand how cDCs are being regulated in different
and diverse tumor microenvironments, with the ultimate goal of enhancing their function
in patients to boost T cell immunotherapy efficacy.

1.5 Immune contexture of pancreatic cancer
There has been a push in recent years to classify cancers based on their
potential

for

immunotherapy

success,

to

predict

which

patients

will

likely

benefit/respond. Tumor-infiltrating lymphocyte (TIL) presence and location is an
important readout, complemented by numerous other variables such as tumor
mutational burden (Cristescu et al., 2018) and inhibitory checkpoint ligation in the tumor
(Teng et al., 2015). PDAC has been traditionally used as a prime example of a “cold”
tumor characterized by low mutational variety and relatively low number of tumorinfiltrating CD8+ T cells and NK cells. More refined dissection of human tumors has
revealed abundant heterogeneity based on tumor-intrinsic drivers and stromal
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signatures (Bailey et al., 2016b; Moffitt et al., 2015), and there is now active interest in
tailoring treatments for different subtypes. There is increasing evidence for presence of
immunogenic neoantigens and high TIL infiltrates in subsets of PDAC patients (Bailey et
al., 2016a; Balachandran et al., 2017; Balli et al., 2017; Carstens et al., 2017). It is now
appreciated that tumor mutational burden does not necessarily correlate with
immunogenic antigens, and there is a need to understand why PDAC patients with
‘actionable’ immunogenicity still do not mount an effective immune response.
The predominance of immunosuppressive cells in the PDAC microenvironment is
undisputed. These myeloid-origin cells have been demonstrated to seed very early in
PDAC pathogenesis, and setup a hostile environment for any anti-tumor activity (Clark
et al., 2007; Mitchem et al., 2013; Stromnes et al., 2014; Zhang et al., 2017c). This is
associated with pathologic fibrosis that forms another barrier to therapy and immune
recognition (Jiang et al., 2017). Other immune cells, notably B cells, CD4+ T cell
subsets, and gdT cells have also been shown to get co-opted by tumoral cues to drive
PDAC progression (Daley et al., 2016; Pylayeva-Gupta et al., 2016; Zhang et al., 2014),
demonstrating the extreme immune dysfunction in this disease. Given these abnormal
immune responses detailed in preclinical and clinical studies, we were interested in
determining how host immunity responds to spontaneous PDAC, and how this immune
response is subverted or evaded. This central question forms the basis for my
dissertation project.
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1.6 Figures
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Figure 1.1 – Pancreatic adenocarcinoma (PDAC) progression
Pancreatic adenocarcinoma originates primarily from intraepithelial neoplasms
(PanINs). Upon acinar-to-ductal metaplasia, cells of acinar origin transform and become
neoplastic driven predominantly by oncogenic Kras signaling and reinforced by ductal
differentiation programs. PanINs are graded from stages 1 to 3; stage 1 being
characterized by appearance of columnar, mucinous epithelium and with increasing
architectural disorganization and nuclear atypia through stages (marked in each image
with yellow arrowheads). During this transition, other characteristic alterations arise
such as loss of TP53, INK4A, ARF and/or SMAD4 function or enhanced developmental
pathways such as Notch, Hedgehog and Hippo signaling. These mutational steps are
concomitant with sustained mitogenic signaling pathways such as RAF/MAPK, PI3K/Akt or JAK/STAT3 signaling axes, which characterize PDAC tumorigenesis and
influence its immune landscape (Hezel et al., 2006). High-grade PanINs ultimately
transform into frank PDAC with invasion beyond the basement membrane.
Immunologically, PDAC initiation is followed by uncharacteristic infiltration of
immature

myeloid

cells,

including

inflammatory

monocytes,

tumor-associated

macrophages and granulocytes. This early seeding is known to setup an
immunosuppressive microenvironment along with activation of fibroblasts and stromal
deposition. Lastly, the PDAC microenvironment is known to be especially hostile to
CD8+ T cell activity and infiltration.
CAFs: cancer associated fibroblasts; MDSCs: Myeloid-derived suppressor cells;
TREGS: CD4+ FOXP3+ regulatory T cells
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Figure 1.2 – Steps in anti-tumor T cell immunity cycle
Adaptive immunity and T cell surveillance in tumors is dependent on several steps
and cellular players (Chen and Mellman, 2013). Steps –
(1) In the first step, tumoral antigens (neoantigens or tumor-associated antigens) arising
due to aberrant cellular processes are released in the tumor microenvironment.
(2) A critical step involves uptake and processing of these ‘foreign’ antigens by antigen
presenting cells (APCs) such as DCs or macrophages. These APCs can traffic the
antigen signal to draining lymph nodes of the tumor to expand the immune
response. Of note, if appropriate signals such as inflammatory cytokines do not
accompany this antigen uptake, it can result in peripheral tolerance to the tumor. If
inefficient or indolent APCs such as macrophages ‘crowd out’ the more specialized
DCs, this can also result in wayward T cell responses.
(3) Once in the lymphoid organ, DCs presenting antigen peptide in the context of MHC
molecules can prime naïve T cells that are specific for antigen, and initiate a rapid
expansion of this pool.
(4) These primed/educated effector T cells then traffic to the tumor site and intravasate,
driven by inflammatory and chemokine cues.
(5) Upon infiltrating into the tumor, T cells that specifically recognize and bind to cancer
cells can kill their target (detailed in Figure 1.3). Killing of cancer cell effectively
releases additional tumor antigens to reinforce anti-tumor cytokine production while
increasing the breadth and depth of the response.
Tumors escape this cycle through several means, and this dissertation describes a
potential mechanism in PDAC.
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Figure 1.3 – Dendritic cell–T cell immune synapses
T cell activation is necessary for their cytotoxic activity, and this is mediated by
multiple signals involving DCs .
•

Step 1 involves DCs processing and presenting tumor/foreign antigen peptides to
cognate T cell receptors (TCRs) on CD8+ T cells or CD4+ T cells, through pMHC–I or
pMHC–II complexes, respectively.

•

Step 2 involves co-stimulation by interaction between CD28 on T cell surface and
CD80/CD86 on the DC surface, which reinforces intracellular TCR signaling and
initiates effector programs.

•

Step 3 involves autocrine and paracrine cytokine stimulation (e.g.- IL-2, IL-12, IL-15
etc.) that contextualizes the immune response and can effectively prime or tolerize T
cells towards a certain lineage (e.g.- TH1 or TH2 or TREG).

•

Fully primed and activated CD8+ T cells become cytolytic on recognizing tumor cells,
through the expression of granzymes (Gzm) and perforin (Prf), and the secretion of
cytokines such as interferon-γ (IFN-γ) and tumor necrosis factor (TNF-a).

CD4+ T cells play a crucial role in these steps, as they can support activation of
CD8+ T cells by providing cytokines like IL-2 to promote activation and proliferation, or
IL-21 to promote survival and memory. Another key interaction involves CD40 ligand
(CD40L) on activated CD4+ T cells stimulating CD40 on tumoral DCs, which ‘licenses’
the DCs to enhance their antigen presentation and co-stimulatory capacity and boosts
CD8+ T cell priming (Laidlaw et al., 2016).
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2.1 Focused Introduction
Pancreatic

ductal

adenocarcinoma

(PDAC)

is

notoriously

resistant

to

immunotherapy, including cytokine therapy, adoptive T cell therapy and checkpoint
blockade strategies (Aglietta et al., 2014; Brahmer et al., 2012; Kunk et al., 2016;
O'Reilly et al., 2019; Royal et al., 2010). Failure of these therapies has been frequently
attributed to CD8+ T cell scarcity as well as profound immunosuppression in the PDAC
microenvironment (Beatty et al., 2015; Stromnes et al., 2014; Zhang et al., 2017a).
However, recent studies have challenged this ‘homogenous’ paradigm and revealed
that many PDAC patients indeed harbor intratumoral T cells and potentially actionable
neoantigens that can elicit T cell responses (Bailey et al., 2016a; Bailey et al., 2016b;
Balachandran et al., 2017; Cristescu et al., 2018; Poschke et al., 2016). Human PDAC
patients likely exhibit a modest ‘neoantigen’ repertoire for their host T cell response to
act against, and there is a pressing need to understand why endogenous T cell
responses are still so poor in PDAC, and to eventually develop strategies that
revive/rewire this response. We speculate that multiple steps in the adaptive immunity
cycle are disrupted in PDAC prior to T cell infiltration, hence undermining final T cell
activity and outcomes.
The mechanisms of tumor evasion in the pancreas are worth elucidating as
elegant studies have shown that neoantigen-directed immune response can be
subverted by diverse mechanisms in cancers of different etiologies (DuPage et al.,
2011; DuPage et al., 2012; Gubin et al., 2014; Schietinger et al., 2016). Existing genetic
models for PDAC have not been amenable to study the heterogeneous interactions
between developing tumors and the host adaptive immunity due to a dearth of tumor21

specific neoepitopes (Evans et al., 2016). Transplanted PDAC models are constrained
by their lack of stroma and very distinct inflammatory/immunized milieu upon tumor
grafting, which can mask de novo immune responses (Spear et al., 2019). Elegant
studies have shown tumor-intrinsic factors can be diverse despite similar genetic
background and influence the TME and treatment outcome very distinctly (Li et al.,
2018). Additionally, heterotopic transplant models do not recapitulate other physiological
variables such as the organ vasculature, hypoxia, lymphatic drainage, resident immune
cells, or microbial makeup. Simply put, location matters, and there is a strong case to be
made for studying PDAC immune evasion using spontaneous models of disease.
The success of a cytotoxic T cell response against tumors is dependent on the
initial priming by antigen-presenting cells; chief amongst them being conventional DCs
(cDCs). cDCs have been recognized as critical mediators of antigen-priming and T cell
activity, with Batf3/Irf8-dependent cDC1s being responsible for CD8+ cytotoxic T
lymphocyte (CTL) cross-priming and Irf4-dependent cDC2s being implicated in helper
CD4+ T cell (TH) priming (Gardner and Ruffell, 2016). In addition to their function in T
cell priming, cDCs have been implicated in assisting T cell-dependent tumor killing and
determining response to immunotherapies (Binnewies et al., 2019; de Mingo Pulido et
al., 2018; Roberts et al., 2016; Salmon et al., 2016; Spranger et al., 2017). DCs are
generally a rare population and outcompeted in the PDAC TME by other myeloid cells
such as macrophages and granulocytes (Engelhardt et al., 2012). Studies on DCs in
PDAC models have focused on tolerogenic subsets (Barilla et al., 2019; Bellone et al.,
2006; Jang et al., 2017; Ochi et al., 2012). We hypothesize the quality and function of
these cDCs in the PDAC TME can influence the lack of T cell responses observed.
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2.2 Summary and scope
In this study, we set out to determine how antigen-specific anti-tumor immunity is
disrupted during progression of autochthonous PDAC.
Using several genetic mouse models described herein, we show that early
pancreatic lesions fail to elicit sufficiently effective tumor-limiting TH1 and CD8+ CTL
responses despite recognition of neoantigen. Instead, the fibro-inflammatory pancreatic
microenvironment favors the expansion of tumor-promoting TH2 and TH17 responses.
This is in contrast to similarly progressing lung adenocarcinomas, suggesting
differences in immune response programming. We identify one of the fundamental
reasons for aberrant neoantigen-directed responses in pancreatic lesions to be the
paucity of conventional dendritic cells, specifically cDC1s. The relatively lower number
of cDC1s in the pancreas are excluded from tumor parenchyma, additionally their
antigen trafficking and presentation functions are disrupted. This corresponds with
similar observations of cDC1 scarcity in human PDAC patient datasets.
Our results provide insight into how cDC activity can be reestablished in the
pancreatic tumor microenvironment (TME) to drive better anti-tumor T cell-driven
responses. We utilize DC–mobilization and –licensing strategies in our genetic models
of PDAC and elicit enhanced T cell infiltration, generating tumor–controlling immunity
and systemic responses. We also demonstrate the value of such DC–targeted therapy
in augmenting efficacy of radiation therapy. These translationally relevant findings
underscore the importance of targeting cDCs as a myeloid population in the TME of
PDAC.
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2.3 Results
Neoantigen expression during pancreas cancer development elicits antigenspecific responses
The “KPC” genetic mouse model of pancreas cancer has been widely used
because of its fidelity to human PDAC, including genetic alterations in KrasLSL-G12D and
loss of Trp53, associated desmoplasia, and inflammation (Hingorani et al., 2003; Morton
et al., 2010). The model also mirrors human disease in its resistance to both cytotoxic
and immunotherapies (Beatty et al., 2011; Gopinathan et al., 2015). However, KPC
mice seldom develop additional genetic alterations that would drive prominent
neoantigens for studying antigen-specific immune responses and immune evasion
(Evans et al., 2016; Li et al., 2018). Studies that have assessed the impact of
antigenicity have utilized heterotopic or orthotopic tumor grafts that do not recapitulate
normal pancreas cancer progression and have very divergent immune contexture and
poorly representative desmoplasia (Spear et al., 2019). To study antigen-specific
responses in the context of de novo pancreas cancer development, we engineered a
mouse designed to express a model antigen chicken ovalbumin (OVA) bicistronically
with green fluorescent protein (GFP) under the control of both Cre activation and
tetracycline repression (R26tm1(LSL-OG) or OG, Figure 2.1A). The presence of
neoepitopes for CD8+ T cell, CD4+ T cells and B cells allows us to study OVA-specific
cellular and humoral immunity raised during the course of tumor progression. These
‘OG’ mice were crossed to KPC background to create ‘KPC-OG’ mice.
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We sought to test several key parameters of this model, including antigen expression,
CD8+ T cell recognition and central tolerance. Using KPC-OG mice and cell lines
derived from late stage tumors in these mice (KP-OG cells), we found that PDAC cells
express OVA and GFP which can be repressed by administration of doxycycline
(Figure 2.1A). Notably, similar to other lineage-tracing studies in this model (Rhim et
al., 2012), GFP and presumably OVA were expressed concomitant with early
transformation and induction of metaplasia. As such, >95% of cytokeratin 19+ (CK19)
ductal cells co-expressed GFP (Figure 2.1B). Tumor lines derived from this model
express MHC-I at equivalent levels to non-antigenic KPC (Figure 2.2A). To assess
functional antigen presentation by KPC-OG tumor cells, we performed T cell killing
assays ex vivo using OVA-specific OT-I CD8+ T cells and found T cells both recognized
and killed KPC-OG-derived cells in an antigen-dependent manner (Figures 2.1C and
2.2B). In order to verify that endogenous antigen-specific T cells generated in OG+ mice
were not subjected to central tolerance, we vaccinated tumor-free p48-Cre;Trp53fl/fl;OG
(PC-OG) mice with OVA and observed a clear enrichment of dextramer+ OVA-specific
CD8+ T cells in peripheral blood and draining lymph nodes (Figure 2.2C). Furthermore,
we implanted KPC-OG-derived tumor cells into PC-OG or PC (control) littermates in the
presence or absence of doxycycline. We observed that grafted KP-OG cells grew
equally slowly in PC-OG and PC mice, but doxycycline repression of OVA expression
accelerated tumor progression (Figure 2.2D). Together, these data suggest that p48Cre-driven OVA expression in the pancreas does not limit the OVA-specific T cell
repertoire by thymic deletion, and that KP-OG cells can indeed elicit immune responses
in a graft setting.
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To determine the impact of robust neoantigen expression at tumor initiation
stages, we analyzed immune infiltrates in pre-cancerous lesions of KPC-OG or KPC
mice. At early stage of tumorigenesis (6 weeks), we observed increased infiltration of
CD8+ and CD4+ T cells and B220+ B cells in KPC-OG mice when compared with KPC
littermates, by immunohistochemistry and flow cytometry (Figures 2.1D–E). To assess
antigen-specific responses, we assayed for OVA-specific CD8+ T effector cells in situ.
As expected, we observed increased numbers of OVA-dextramer+ CD8+ T cells in premalignant pancreas, draining lymph nodes (dLN) and spleen of early stage KPC-OG
compared to non-tumor bearing PC-OG mice (Figure 2.1F). We found that doxycycline
withdrawal at birth was equivalent to untreated KPC-OG mice with similar OVA-specific
T cells, so we did not treat with doxycycline going forward. Interestingly, compared to
control animals, the dextramer+ CD8+ T cells in KPC-OG pancreas had higher Ki67+
frequency; but >30% of these cells were PD1hi/TIM3hi, suggesting an early
exhausted/dysfunctional phenotype (Figures 2.2E–F). This recapitulates observations
in liver cancer models that found a reversibly-dysfunctional phenotype (Schietinger et
al., 2016). To ascertain if there was a systemic response towards tumor neoantigens,
we measured OVA IgG levels in serum. We found total IgG1 to be similar between
KPC-OG and KPC littermates, but OVA-specific IgG1 titers in KPC-OG serum were
markedly higher than age-matched controls (Figure 2.2G). Together, these data
suggest that there is an antigen-directed adaptive immune response in KPC-OG
pancreas during initial stages of tumorigenesis. These observations underscore that
immunogenic neoantigens can be recognized by endogenous surveillance early in
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pancreatic tumorigenesis, signifying that early pancreatic lesions do not grow out in an
immune-privileged environment.

Neoantigen expression accelerates PDAC progression but restrains lung
adenocarcinomas
To evaluate the impact of neoantigen expression on pancreatic cancer
progression we employed three distinct PDAC models. We utilized the KPC-OG mouse
(p53fl/+) and validated our findings in the KPPC-OG model (p53fl/fl version), which
exhibits faster progression. Surprisingly, in both models we found that OG expression
accelerated tumor progression at every stage of disease. In early stage KPC-OG mice
at 6 weeks, we found that OG expression led to a marked increase in intraepithelial
neoplasia (PANIN) area, higher grade PANIN lesions and increased tumor cell
proliferation (Figures 2.3A–B and 2.4A). Associated with this early disease progression
was an increased desmoplastic response as measured by higher collagen density and
α-SMA+ fibroblasts (Figures 2.3C–D, and 2.4B). Analysis of the inflammatory infiltrates
indicated an increased infiltration of neutrophils, eosinophils and macrophages, but not
NK, NKT or gdT cells (Figures 2.3E, 2.2H and 2.4C). To better understand signaling
pathways promoting this phenotype, we conducted bulk RNA sequencing of KPC-OG
and KPC lesions. We observed enrichment of mitogenic pathways (including MAPK,
EGFR and TNF signaling), enhanced inflammatory processes, along with a robust
upregulation of EGFR ligands and pro-inflammatory myeloid mediators (Figure 2.4D,
Tables 2.1 and 2.2). Histologically, we saw a corresponding increase in activated ERK,
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STAT3 and EGFR signaling in KPC-OG tumor lesions (Figure 2.4E).

As disease

progressed, OG+ mice had higher grade tumors, markedly more liver metastases, and
reduced overall survival (Figures 2.3F–H).
To address the issue that p48-Cre recombination occurs early in pancreas
development, we employed an inducible Pdx1-Cre-ERTM driver (Gu et al., 2002). We
generated Pdx1-Cre-ERTM;KrasLSL-G12D;Trp53fl/fl;OG mice, denoted iKPC-OG. We
induced sporadic recombination in iKPC-OG mice by tamoxifen administration at 5weeks, which led to mosaic activation in a field of normal acini (Figure 2.4F). Despite
these differences in tumor initiation, iKPC-OG mice ultimately developed higher grade
tumors, had reduced overall survival and increased liver metastases compared to iKPC
littermates (Figure 2.3I). Collectively, these observations demonstrated that a
neoantigen-directed response in the pancreatic TME results in exacerbation of tumor
progression.
Previous work in analogous KP lung models showed that neoantigen recognition
leads to productive immunity and restrains tumor progression (DuPage et al., 2011). To
mirror these studies in our model system, we intra-tracheally administered Cre to
KrasLSL-G12D;Trp53fl/fl;R26tm1(LSL-OG) (KPL-OG) or OG-negative littermate mice (KPL) to
generate lung adenocarcinomas and assess the impact of antigenicity (Figure 2.4G). In
agreement with previous studies, we observed increased numbers of CD8+ and CD4+ T
effector cells, lower tumor burden and decreased disease grade in KPL-OG mice
compared to control (Figures 2.3J, 2.3K, and 2.4H). These data suggest that OG
expression in the lung and pancreas elicit different tumor progression outcomes.
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One of the pathways by which tumors escape immune surveillance is through
loss of expression of prominent neoantigens, also known as immune-editing (O'Donnell
et al., 2019; Schumacher and Schreiber, 2015). To test the propensity for antigen loss
as an evasion mechanism in our model, we analyzed end stage KPC-OG and KPL-OG
tumors for persistence of neoantigen expression. KPL mice exhibited substantial loss of
GFP expression as tumors advanced (Figure 2.3L). However, in all three models of
pancreatic cancer we found no evidence of antigen loss either at the primary site or in
liver metastases (Figures 2.3L and 2.4I). To further verify these contrasting results, we
administered Ad-Cre intramuscularly to create KP-OG+ sarcomas (DuPage et al., 2012).
Mirroring observations in the lung, we observed substantial loss of GFP in advanced
sarcomas (Figure 2.4J). Taken together and consistent with previous reports, these
data indicate that immunogenic lung tumors and sarcomas elicit an early immune
response that delays tumor progression, but neoantigenicity is lost or silenced with
progression. In contrast, we observe that neoantigen expression in pancreatic lesions
results in disease progression without antigen-loss.

Neoantigen expressing PDAC tumors are poorly responsive to immunotherapy
Lack of high mutational and/or neoantigen burden has been proposed to explain
the poor responsiveness to immunotherapy in human PDAC patients. A complementary
but not mutually exclusive hypothesis is that the PDAC TME enforces this lack of
responsiveness to immunotherapy, even when tumor antigens are present (Clark et al.,
2009; Kieler et al., 2018; Salmon et al., 2019; Sharma et al., 2017). To determine if OVA
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expression leads to improved responsiveness in PDAC, we tested efficacy of
checkpoint- and adoptive T cell-therapy. We treated KPPC-OG mice upon ultrasoundbased diagnosis of established tumors, with anti-PD1 and anti-CTLA4 IgGs. Checkpoint
therapy alone did not impact survival, agreeing with previous studies (Jiang et al., 2016;
Steele et al., 2016; Winograd et al., 2015) (Figure 2.4K). To model the impact of
adoptive T cell-therapy, we utilized exogenously activated OT-I CD8+ T cells. We
treated diagnosed KPPC-OG mice with three rounds of OT-I adoptive transfer
supplemented with IL-2 and observed a modest survival benefit associated with loss of
neoantigen (Figures 2.3M and 2.3N). These data reveal that endogenous tumoral
CD8+ T cells are unsurprisingly stunted in later stages of PDAC and suggest that
unlocking existing tumoral CD8+ T cells against neoantigen burden does not control
tumor. However, limited ‘immune pressure’ can be re-established in PDAC by providing
sufficient numbers of activated antigen-directed CD8+ T cells, which is in agreement
with previous reports (Stromnes et al., 2015).

Pro-inflammatory CD4+ T cell responses drive PDAC acceleration in response to
neoantigen
Our data suggest that neoantigen expression leads to adaptive immune
responses that surprisingly drive tumor progression. Previous studies have shown that
CD4+ T cells or activated B cells can drive pathogenic inflammation and accelerate
PDAC progression (Barilla et al., 2019; Gunderson et al., 2016; McAllister et al., 2014;
Pylayeva-Gupta et al., 2016; Zhang et al., 2014). Thus, we evaluated if CD4+ T or B
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cells were critical for the early stage disease progression observed in OG+ mice. We
found that while B cell depletion did not alter tumor progression, CD4+ T cell depletion
led to a decrease in premalignant disease burden and PANIN grade, reduced collagen
density and decreased α-SMA+ fibroblast accumulation (Figures 2.5A–C, 2.6A and
2.6B). These data suggest CD4+ T cells accelerate pancreatic neoplasia in response to
neoantigen expression. We next evaluated the polarization of CD4+ T cell responses in
OG+ mice. Consistent with an expansion of both TH2 and TH17 signatures, we observed
higher numbers of pancreas-infiltrating ROR-gt+ and GATA3+ CD4+ TH cells, and more
CD4+ TH cells producing IL-17A, TNF-α, IL-4, and IL-10 (Figures 2.5D–E, and 2.6C–E).
This was partly corroborated by our transcriptomic analyses that indicated IL-17 and
TH17 inflammation enrichment in KPC-OG lesions (Figure 2.4D). We did not see
increased frequency of Tbet+ or IFN-g-producing TH cells (Figure 2.6F). Also, partial
depletion of FOXP3+ TREGS showed no impact on OG+ tumor progression (Figures
2.6G–H). To determine if these observations were specific to the pancreas, we
compared TH cell polarization in OG+ pancreatic lesions with that in lung. Early KPCOG-infiltrating CD4+ TH cells had higher frequency of GATA3+ and ROR-gt+ TH cells
compared to lung; contrastingly KPL-OG tumor-infiltrating CD4+ TH cells were more TH1skewed with increased frequency of Tbet+ and IFN-g-producing TH cells (Figures 2.6I–
J). Upon neutralizing proinflammatory IL-17 signaling, we observed lower disease
burden and pathological fibrosis (Figures 2.5F–H). These data suggest that neoantigen
expression early in PDAC tumorigenesis enhances TH2- and TH17-polarized CD4+ T cell
infiltration, which have been associated with inducing pancreatitis-like fibro-inflammatory
TME and driving disease progression (Alam et al., 2015; McAllister et al., 2014; Zhang
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et al., 2018). We found the increased activation of pERK1/2, pSTAT3 and pEGFR
signaling was attenuated in KPC-OG mice treated with anti-CD4 depletion or IL-17
signaling neutralization (Figures 2.5I). Overall, these data indicate that increased
infiltration of antigen-responsive pathogenic CD4+ TH17 cells is partly responsible for
driving more rapid PDAC progression, in line with previous reports (Liou et al., 2013;
Zhang et al., 2017a; Zhang et al., 2014).

cDCs are fewer and less functional at peripheral priming in PDAC compared to
lung cancer
We sought to determine the cellular origins for differences in T cell responses
against neoantigenicity in the lung and pancreas. To do so, we performed systematic
immune profiling of all major innate immune cell subsets in both early- and late-stage
lung and pancreas tumor tissues and found that conventional dendritic cells (cDCs)
were among the most divergent, especially at later stages (Figures 2.7A, 2.8A and
2.8B). cDCs have been shown to be integral in mounting and shaping both CD8+ and
CD4+ T cell-driven immune responses against tumors (Bottcher and Reis, 2018;
Gardner and Ruffell, 2016), and absence or dysfunction of DCs can magnify
unproductive TH cell responses (Furuhashi et al., 2012; Ibrahim et al., 2012; Ochi et al.,
2012). In early premalignant stages, we observed CD103+ CD24hi cDC1s were 10-fold
fewer and CD172a+ CD11b+ cDC2s were 4-fold fewer in the pancreas when compared
to lung. The disparity in cDC1s was magnified at later stages, with cDC1s in PDAC
being 79-fold less than in counterpart lung adenocarcinomas (Figure 2.7B). These
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observations were not impacted by OG expression. We also observed fewer migratory
CD103+ DC1s and CD11b+ DC2s in pancreas-dLNs of KPC-OG mice when compared
to lung-dLNs of KPL-OG mice, but no major difference in resident DC populations
(Figures 2.7C and 2.8C). To determine possible differences in cDC localization
between the pancreas and lung TME, we transplanted irradiated KPC and KPL mice
with Zbtb46gfp and Snx22gfp bone marrow (BM). The Zbtb46gfp reporter model marks
all cDCs (Satpathy et al., 2012a), while the Snx22gfp model labels Batf3-dependent
cDC1s (Brahler et al., 2018) (Figure 2.8D). Using IHC to quantify GFP+ cells, we
observed similar patterns to our flow cytometric results with markedly more Zbtb46GFP+ cDCs and Snx22-GFP+ cDC1s in lung when compared to pancreas, both in
premalignant tissues and late stage cancer (Figure 2.7D). We next analyzed cDC
localization relative to tumor cells and found that both Zbtb46-GFP+ cDCs and Snx22GFP+ cDC1s localize closer to lung tumors (>60% were within 5 µm or less) but are
more distant from tumor nests in PDAC (Figure 2.7E). These cDCs, especially cDC1s
in PDAC had lower co-stimulatory markers such as CD80, CD86 and MHC–I, and lower
maturation markers such as OX40 when compared to lung tumors (Figure 2.8E). When
freshly isolated cDCs from advanced pancreatic or lung tumors were co-cultured with
respective T cells, we observed the PDAC DCs to be less functional at antigen
presentation and T cell activation ex vivo (Figure 2.8F). The higher cDC1 density in
lung cancer also paralleled higher CD8+ T cell and OVA-specific CD8+ T cell density,
suggesting a critical role in antigen-specific T cell immunity (Figure 2.7F). This was
further supported by the observation that depleting cDC1s prior to KPL-OG lung tumor
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initiation via Batf3-/- bone marrow transplant results in drastically reduced CD8+ T cell
infiltration (Figure 2.8G).
To determine if these observations in mouse models held true in human
pancreatic tumors, we analyzed cDC density in human PDAC tissue by mass cytometry
and publicly available datasets. Using mass cytometry, we found that cDC1s specifically
are extremely rare and ~100-fold less abundant when compared to tumoral
macrophages (TAMs) or neutrophils in human PDAC tissues (Figure 2.7G).
Additionally, normalized cDC1 gene signature levels (Barry et al., 2018; Bottcher et al.,
2018; Spranger et al., 2017) are much lower in PDAC when compared to lung
adenocarcinoma (Figure 2.7H). These observations mirror our mouse models and
indicate that cDCs, specifically cDC1s, are awfully/quite rare in human PDAC tissue and
relatively abundant in lung cancers.
One major function of cDCs in anti-tumor immunity involves antigen sampling
and migration to tumor-dLN to prime new T cell responses. To assess this priming
function, we bred LSL-ZsGreen (ZsG) mice into KPC or KPL mice. ZsGreen expressed
by transformed tissue is lysosome stable (Roberts et al., 2016) and enables us to track
antigen uptake and trafficking by different antigen presenting cells (APCs) in the TME
and tumor-dLN. We observed ZsGreen throughout transformed pancreatic and lung
lesions; and TAMs, cDC1s, and cDC2s robustly took up ZsGreen from malignant cells
in both tissues (Figure 2.8H). However, there were stark differences in the frequency of
ZsGreen+ migratory cDC1s and cDC2s in tumor draining lymph nodes. Across multiple
time points, significantly more migratory cDCs were ZsGreen+ in KPL-ZsG mice when
compared to stage-matched KPC-ZsG mice (Figure 2.7I). Most striking was the fact
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that in early stage KPC-ZsG mice, nearly no migratory cDCs trafficked tumor-derived
ZsGreen, despite clear antigen expression in lesions and loading on intrapancreatic
cDCs at this stage. To determine if poor “antigen-trafficking” by migratory cDCs at early
stages of pancreatic tumorigenesis influenced antigen-specific T cell priming, we
analyzed OVA-specific CD8+ T cells in the tumor dLNs of OG+ mice. We found that
KPC-OG pancreas-dLN had far fewer OVA-specific CD8+ T cells compared to stagematched KPL-OG dLN (Figure 2.7J). Collectively, these data suggest that T cell
priming by cDCs against neoantigens expressed in developing PDAC is less functional
compared to lung adenocarcinomas.

Mobilizing cDCs into early pancreatic lesions can reverse fibro-inflammatory
responses
We next tested if increasing cDCs in early stages of developing PDAC could
enhance TH1 and CTL activity and overcome inflammation-induced progression
observed in KPC-OG mice. To accomplish this, we stimulated hematopoietic
mobilization of DC precursors using Fms-related tyrosine kinase 3 ligand (Flt3L)
treatment (Hammerich et al., 2019a; Meyer et al., 2018; Salmon et al., 2016). We found
that Flt3L administration at early stages of tumorigenesis resulted in robust infiltration of
cDCs in the pancreas with a 10-fold increase in cDC1s (Figure 2.9A). These data
suggest that when cDC precursors are mobilized in excess, they can successfully
infiltrate early pancreatic lesions. Previous studies have indicated that certain DC
subsets can have a protective role during pancreatitis (Bedrosian et al., 2011), and we
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speculated that expanding cDCs might elicit a similar phenotype in developing PDAC.
Remarkably, we observed that Flt3L treatment alone could revert much of the disease
acceleration and fibro-inflammatory pathology in KPC-OG mice. Compared to untreated
mice, Flt3L-treated KPC-OG mice had a reduced lesion area, lower grade PANIN
lesions, as well as reduced collagen deposition and α-SMA+ fibroblast density (Figures
2.9B–D, and 2.10A). Flt3L treatment reduced the number of ROR-gt+ IL-17A-expressing
TH17 cells and GATA3+ TNF-α-expressing TH2 cells and maintained IFN-g producing
TH1 cells (Figures 2.9E–F, 2.10B–D). Notably, there was a sharp reduction in the
density of pathogenic TNF-α-expressing TH cells (Figure 2.10E). While the absolute
number of total CD8+ CTLs did not increase with Flt3L treatment, these CTLs were more
proliferative and now frequently adjacent to pancreas lesions (Figures 2.9G–H, and
2.10F) and more of these CTLs were producing IFN-g+ and TNF-α+ suggesting better
cytotoxicity (Figure 2.9I). To determine if these changes were functional, we depleted
CD8+ T cells or IFN-g and found it abolished the tumor control by Flt3L treatment
(Figure 2.9J). Concurrently, we found CD8+ T cell depletion attenuated increases in the
tumor cell-death and antigen-editing observed in Flt3L-treated KPC-OG mice (Figures
2.10G–H). Together these data suggest that restoring cDC numbers at early stages of
pancreatic tumorigenesis resulted in disease restraint and more favorable anti-tumor T
cell responses.
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Enhancing cDC infiltration and activation in established PDAC leads to disease
stabilization
The impact of Flt3L treatment at early stages of pancreatic tumorigenesis raised
the possibility that Flt3L-based cDC mobilization in established pancreatic tumors could
benefit anti-tumor immunity. Additionally, our previous work has shown that established
PDAC in human patients and KPC mouse models can impair cDC1 development in the
bone marrow (Meyer et al., 2018) and therapeutic strategies might require boosting cDC
development and/or mobilization to overcome this disruption. Thus, we treated KPPCOG mice with Flt3L upon PDAC diagnosis. In contrast to early-stage treatment, there
was no appreciable impact of Flt3L alone on tumor progression. The regimen was
successful in increasing cDC1 and cDC2 infiltration into established tumors and
migration into dLN (Figures 2.11A and 2.11B). Notably, Flt3L-driven increases in cDCs
were noticeably more modest in PDAC tissues compared to premalignant pancreas
tissues (Figure 2.11A). Administering Flt3L alone did not change intratumoral CD8+ T
cell phenotype; instead there was an enrichment of TREG frequency (Figure 2.11C). This
finding is in line with previous reports (Ager et al., 2017; Salmon et al., 2016), and our
data suggest that increasing mobilization of cDC progenitors into circulation is
insufficient in generating favorable T cell responses in established PDAC.
We speculated that the lack of impact of Flt3L on CTL and TH cell infiltration
could be due to ineffective licensing of incoming cDCs, allowing for the immature DCs to
become tolerogenic in the PDAC TME. To overcome this barrier, we used two
approaches. In separate cohorts, we either intratumorally injected a STING agonist
(RR-S2-CDA) to influence IFN-dependent DC maturation (Corrales et al., 2015; Sivick
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et al., 2018), or systemically administered CD40-agonist IgGs to enable better licensing
and enhance APC function and survival (Beatty et al., 2011; Byrne and Vonderheide,
2016). Unlike other tumor models (Kinkead et al., 2018; Ma et al., 2019), we found that
neither CD40 nor STING agonist alone enhanced cDC abundance in the PDAC TME.
However, combination of either agent with Flt3L worked synergistically to drive massive
influx of cDC1s and cDC2s, with CD40 agonist showing clear superiority, driving a >64fold increase in cDC1s (Figure 2.11D). Phenotypically, cDC1s had higher MHCI and
MHCII expression and modestly higher CD80/CD86 expression upon CD40 agonist and
Flt3L treatment (Figure 2.12A). Notably, combination treatment with CD40 agonist and
Flt3L did not mobilize more pre-cDCs than Flt3L treatment alone, suggesting that the
observed synergism was in the PDAC TME (Figures 2.12B and 2.12C).
We next assessed the impact of CD40 agonist and Flt3L combination on tumor
immunity. While CD40 or STING agonist alone modestly enhanced CD8+ T cell
infiltration, combination with Flt3L triggered markedly enhanced intratumoral CD8+ CTL
and CD4+ TH cell infiltration without TREG induction (Figure 2.11E). Additionally, CD40
agonist plus Flt3L combination treatment increased the abundance of intratumoral OVAspecific CD8+ T cells (Figure 2.11F). We found that more CD8+ CTLs were in close
proximity and frequently in contact with PDAC cells of CD40 agonist plus Flt3L
combination-treated mice (Figure 2.11G). Notably, the CD40 agonist plus Flt3L
treatment elicited integrated anti-tumor responses involving marked increases in
infiltrating NK cells, NKT cells and gdT cells (Figures 2.11H and 2.12D). This dual
treatment resulted in significant loss/silencing of GFP in extant KPPC-OG tumors,
suggesting immune evasion under T cell pressure (Figure 2.12E).
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Due to the substantial changes observed in cDC numbers upon anti-CD40 plus
Flt3L combination treatment, we next tested priming capacity in PDAC-dLNs using
KPPC-ZsG mice. We found a considerable increase in ZsGreen+ migratory cDC1s
trafficking tumor antigen to dLN of CD40 agonist plus Flt3L-treated mice (Figure 2.11I).
To determine if this enhanced antigen trafficking results in better peripheral crosspriming, we analyzed the enrichment of antigen-specific CD8+ T cells in the dLN of
treated KPPC-OG tumors. There was a 6.7-fold increase in OVA-specific CD8+ T cells in
dLN of the anti-CD40 plus Flt3L treatment cohort, compared to a 3.5-fold increase in the
anti-CD40 only cohort (Figure 2.11J). This suggested that combination treatment was
efficacious in improving T cell priming in PDAC-dLNs.
Histologically, KPPC-OG tumors undergoing combination treatment had a greatly
altered TME. Tumors receiving Flt3L and CD40 agonist had no major changes in total
PDPN+ fibroblast presence, but substantially lower amount of fibrosis and a clear
reduction in desmoplastic α-SMA+ fibroblasts (Figures 2.11L–M, and 2.12J). We
observed higher MMP9 production in the dual-agent treated TME, suggesting increased
myeloid-cell dependent matrix remodeling (Figure 2.12K)(Long et al., 2016). Interpreted
in the context of increased CTL infiltration, this suggested that cDC mobilization and
polarization renders the PDAC microenvironment more accessible and conducive to
CTL activity. Combining Flt3L administration with either CD40 or STING agonist
resulted in improved disease control beginning a week into either treatment (Figure
2.11K). Combining CD40 agonism and Flt3L was equally effective in the non-antigenic
KPPC model (Figures 2.12F and 2.12G). We also note the efficacy of this strategy was
dependent on adaptive immunity, as depleting T cells abolished tumor control (Figures
39

2.12H and 2.12I). While this strategy was clearly impactful compared to single-agents,
these data suggest that immune remodeling alone is insufficient to drive tumor
regression in this disease model.

cDC-directed therapy renders PDAC responsive to radiation therapy
While we found that CD40 agonist plus Flt3L reshaped the immune response, we
did not observe tumor regression. A possible explanation is that immune priming and
“antigen-spill” by tumor cell death is very limited in this model (Vonderheide, 2018). One
effective modality to induce immunogenic cell death and boost CTL priming by APCs is
radiation therapy (RT) (Ngwa et al., 2018; Twyman-Saint Victor et al., 2015). RT in
human PDAC patients has limited benefit and is mostly palliative (Balaban et al., 2016),
possibly because the TME does not support induction of tumor immunity. To test if
boosting cDCs could provide the necessary induction and synergize with RT, we
combined anti-CD40 agonist and Flt3L treatment with radiotherapy. We utilized microcomputed tomography (µCT)-guided RT to provide 3 fractionated doses of 8 Gy
directed to KPPC-OG pancreata after cDCs were mobilized. While RT alone only
modestly impacted tumor progression, the triple-therapy resulted in tumor regression in
the majority of KPPC-OG animals (Figures 2.13A–C). Similar results were observed in
orthotopic Kras-Ink tumors suggesting these responses were not specific to the GEMM
or expression of exogenous antigen (Figures 2.13D–F). Notably, the triple-therapy
reduced endstage tumor burden and extended survival over RT alone (Figures 2.13G
and 2.14A). A different treatment strategy involving RT at the induction step also

40

yielded similar efficacy and survival benefit in the KPPC GEMM (Figures 2.13H–J).
Together, these data in 3 different models suggest that augmenting cDCs might be
desirable for RT to be fully effective in PDAC and that CD40 agonist plus FLT3L can
achieve this outcome.
Lastly, as proof-of-concept, we demonstrate that traditional checkpoint inhibition
therapy (anti-PD1 and anti-CTLA4) in conjunction with DC therapy yields superior
outcomes over either treatment alone (Figure 2.14B).
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2.4 Figures
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Figure 2.1 – Neoantigen expression during pancreas cancer development elicits
antigen-specific responses
(A) Genetic loci for KPC-OG model and (BELOW) representative immunoblot of OVA
and GFP expression in KPC-OG-derived cell line 72 hours after doxycycline
withdrawal. Representative of two independent cell lines.
(B) Gross images (LEFT) of pancreatic tissue at 6 weeks in KPC-OG mice on or off
doxycycline, and (RIGHT) immunofluorescence images of pancreatic tumors at 36
weeks in KPC-OG mice on or off doxycycline from birth.
(C) In vitro killing assay for KPC-OG tumor-derived cell line depicting GFP fluorescence
after 24-hour co-culture with antigen-specific (OT-I TCR) or non-specific (C57Bl/6)
activated CD8+ T cells (CTL). Data consistent across two independent cell lines,
n=3/group.
(D) Representative immunofluorescence images and quantification of CD8+ T cells,
CD4+ T cells and B220+ B cells in 6-week-old KPC-OG

and KPC mice. n=10

mice/group.
(E) Density of CD8+ T cells, CD4+ TH, CD4+ TREG and CD19+CD22+ B cells measured by
flow cytometry in early stage KPC-OG and KPC mice. n=5–8 mice/group.
(F) Density of OVA-specific CD8+ T cells in pancreas, pancreas-dLN, and spleen of
early stage KPC-OG and PC-OG mice. n=3–8 mice/group.
Data were consistent across two independent experiments. Scale bar denotes 100 µm
in (B) and (D). n.s., not significant; *p < 0.05. Error bar represents SEM. For
comparisons between two groups, Student’s two-tailed t-test was used.
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Figure 2.2 – Neoantigen expression during pancreas cancer development elicits
antigen-specific responses, Related to Figure 2.1
(A) Mean fluorescence intensity of extracellular MHC-I expression in cell lines derived
from KPC or KPC-OG mice, with or without 24hour IFN-g stimulation. n=3 lines each.
(B) In vitro LDH release and resazurin-based viability of KPC-OG tumor-derived cell line
KP-OG1 and OVA-transduced KPC-OVA line after 72-hour co-culture with activated
antigen-specific (OT-I TCR) CD8+ T cells. Data consistent in three independent cell
lines; n=3/condition.
(C) Schematic of vaccination strategy in 8-week old PC-OG and negative littermate PC
mice using full-length OVA and Poly(I:C), with quantification of OVA-specific CD8+ T
cells in draining lymph node and blood. n=3–4 mice/group.
(D) Immunofluorescence images (LEFT) of GFP expression in KP-OG1 orthotopic
tumors implanted into PC-OG recipient mice and analyzed at day 14 post-implant;
with (RIGHT) growth kinetics of KP-OG1 orthotopic tumors grown in denoted mice
on or off doxycycline. n=5 mice/group.
(E) Quantification of proliferative (ki67+) OVA-specific CD8+ T cells in pancreas,
pancreas-dLN, and spleen of early stage KPC-OG and PC-OG mice. n=3–8
mice/group.
(F) Frequency of PD1+ and PD1+ TIM3+ OVA-specific CD8+ T cells in pancreas of early
stage KPC-OG and PC-OG mice. n=3–8 mice/group.
(G) Total IgG1 and OVA-specific IgG1 titers in serum of early stage KPC-OG, PC-OG
and KPC mice. LoD denotes limit-of-detection. n=4–10 mice/group.
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(H) Gating strategy for various myeloid infiltrates, B cells, NK cells, NKT cells and gdT
cells in non-lymphoid tissue and lesions.
Data were consistent across two independent experiments. Scale bar denotes 100 µm.
n.s., not significant; *p < 0.05. Error bar represents SEM. For comparisons between two
groups, Student’s two-tailed t-test was used.
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Figure 2.3 – Neoantigen expression accelerates PDAC progression but restrains
lung adenocarcinomas
(A) Representative 1X and 10X H&E images with quantification of lesions in pancreas of
early stage KPC-OG and KPC mice. n=12 mice/group.
(B) Lesion grades for early stage KPC-OG and KPC pancreas. n=12 mice/group.
(C) Sirius Red fibrosis staining with quantification in early stage KPC-OG and KPC mice.
n=12 mice/group.
(D) aSMA staining with quantification in early stage KPC-OG and KPC mice. n=12
mice/group.
(E) Flow cytometric quantification of various myeloid infiltrates in early stage KPC-OG
and KPC mice. n=5–6 mice/group.
(F) Kaplan-Meier survival curve for KPPC-OG mice compared to KPPC negative
littermates. n=14–20 mice/group.
(G) Representative H&E images of late stage KPC-OG and KPC mice with quantification
of high-grade tumors. n=14–16 mice/group.
(H) Representative H&E images of late stage KPC-OG and KPC livers with
quantification of metastases. n=14 mice/group.
(I) Kaplan-Meier survival curve for Pdx1-Cre-ERTM-driven iKPC-OG mice compared to
iKPC negative littermates, with quantification of liver metastases. n=8–10
mice/group.
(J) Density of CD8+ T cells measured by flow cytometry in early stage KPL-OG and KPL
lung lesions. n=5 mice/group.
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(K) Representative H&E images of early stage KPL-OG and KPL lung with quantification
of lesion area and tumor grade. Lesions demarcated by yellow line. n=5 mice/group.
(L) Representative immunofluorescence images and quantification of GFP expression
(green) in CK19+ lesions (red) of late stage KPC-OG tumors or H&E-validated
lesions of late stage KPL-OG tumors. GFP-negative or -low lesions in KPL-OG
tumors are demarcated by yellow arrowhead. n=6–8 mice/group.
(M)Kaplan-Meier survival past treatment start for KPPC-OG mice undergoing OT-I
adoptive transfer therapy, compared to untreated controls. n=10–18 mice/group.
(N) Representative immunofluorescence images and quantification of GFP coexpression (green) with CK19+ lesions (red) in KPPC-OG mice subjected to OT-I
adoptive transfer therapy, compared to untreated controls. n=6 mice/group.
Data were consistent across two independent experiments. Scale bar denotes 500 µm
in (A), (C), (D), (G), (H) and (K); bar denotes 100 µm in (L) and (N). n.s., not significant;
*p < 0.05, **p < 0.01. Error bar represents SEM. For comparisons between two groups,
Student’s two-tailed t-test was used. For survival analyses, the Log-rank (Mantel-Cox)
test was used.
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Figure 2.4 – Neoantigen expression accelerates PDAC progression but restrains
lung adenocarcinomas, Related to Figure 2.3
(A) Representative immunohistochemistry images of ki67+ tumor cells with quantification
in early stage KPC-OG and KPC mice. n=6–8 mice/group. Scale bar denotes 100
µm.
(B) Sirius Red fibrosis and aSMA quantification restricted to metaplasia (ADM) and
tumor lesions in early stage KPC-OG and KPC mice. n=12 mice/group.
(C) Density of gdT cells, NK cells and NKT cells measured by flow cytometry in early
stage KPC-OG and KPC pancreas. n=5–6 mice/group.
(D) Table of selected Biological pathways (DAVID BP terms, KEGG terms) and
inflammatory mediator genes significantly upregulated in bulk RNA sequencing of
early stage KPC-OG lesions compared to matched KPC lesions. Adjusted p-value <
0.05 and FDR < 0.05. n=4 mice/group.
(E) Representative images with quantification of p-ERK1/2, p-STAT3 and p-EGFR
immunohistochemistry in early stage KPC-OG and KPC mice. n=10 mice/group.
(F) Strategy for generating Tamoxifen-inducible iKPC-OG mice, with representative
image of pancreatic lesion 4 weeks and 20 wks after tamoxifen administration. Inset
demonstrates mosaic activation. Scale bar denotes 100 µm.
(G) Strategy for generating KPL-OG lung tumors and representative image of lung lesion
12 weeks after AdCre inhalation. GFP-negative or -low lesions are demarcated by
yellow arrowhead. Scale bar denotes 1 mm.
(H) Density of CD4+ TH and frequency of CD4+ TREG cells measured by flow cytometry in
early stage KPL-OG and KPL lung lesions. n=5 mice/group.
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(I) Representative immunohistochemistry image of GFP expression in late stage KPCOG liver metastases with quantification of GFP persistence. Scale bar denotes 500
µm.
(J) Representative immunohistochemistry image of GFP expression in KP-OG sarcoma
8 weeks after AdCre injection. Inset denotes GFP-negative and GFP+ area in KPOG sarcoma. Representative of n=6 mice. Scale bar denotes 500 µm and 100 µm.
(K) Kaplan-Meier survival curve for KPPC-OG mice undergoing anti-PD1/anti-CTLA4
checkpoint blockade, compared to untreated controls. n=8–18 mice/group.
n.s., not significant; *p < 0.05. Error bar represents SEM. For comparisons between two
groups, Student’s two-tailed t-test was used. For survival analyses, the Log-rank
(Mantel-Cox) test was used.
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Figure 2.5 – Pro-inflammatory CD4+ T cell responses drive PDAC acceleration in
response to neoantigen
(A) Representative H&E images with quantification of lesion area (TOP) and grade of
lesions (BOTTOM) in pancreas of early stage KPC-OG mice subjected to perinatal
depletion of CD4+ T cells or CD19+B220+ B cells. n=8–12 mice/group.
(B) Sirius Red staining with quantification in early stage KPC-OG mice subjected to
perinatal depletion of CD4+ T cells or CD19+B220+ B cells. n=8–12 mice/group.
(C) aSMA staining with quantification in early stage KPC-OG mice subjected to perinatal
depletion of CD4+ T cells or CD19+B220+ B cells. n=8–12 mice/group.
(D) Representative flow cytometry plots of RORgt and GATA3 bias in TH cells, with
cellular density of RORgt+ TH17 and GATA3+ TH2 cells quantified in early stage KPCOG and KPC mice. n=3–6 mice/group.
(E) Representative flow cytometry plots of IL-17A and TNF-a expression in TH cells, with
cellular density quantified in early stage KPC-OG and KPC mice. n=3–6 mice/group.
(F) Representative H&E image with quantification of lesion area in pancreas of early
stage KPC-OG mice subjected to IL-17A and IL-17F neutralization. n=8–10
mice/group.
(G) Representative Sirius Red image with quantification in early stage KPC-OG mice
subjected to IL-17A, IL-17F neutralization. n=8–10 mice/group.
(H) Representative aSMA image with quantification in early stage KPC-OG mice
subjected to IL-17A, IL-17F neutralization. n=8–10 mice/group.
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(I) Representative images of p-ERK1/2, p-STAT3, p-EGFR immunohistochemistry in
early stage KPC-OG mice subjected to denoted treatments, with quantification over
overall tissue area and lesion area. n=8–10 mice/group.
Data were consistent across two independent experiments and pooled. Scale bar
denotes 500 µm. n.s., not significant; *p < 0.05, **p < 0.01. Error bar represents SEM.
For comparisons between two groups, Student’s two-tailed t-test was used.
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Figure 2.6 – Pro-inflammatory CD4+ T cell responses drive PDAC acceleration in
response to neoantigen, Related to Figure 2.5
(A) Schematic of perinatal antibody-based depletion strategy and representative flow
cytometry plots depicting depletion of target cell type (CD4+ T cell or B cell) in
pancreas of recipient pups.
(B) Sirius Red, aSMA and ki67 quantification restricted to metaplasia (ADM) and tumor
lesions in early stage KPC-OG mice subjected to perinatal depletion of CD4+ T cells
or CD19+B220+ B cells. n=8–12 mice/group.
(C) Frequency of IL-17A and TNF-a expression in KPC or KPC-OG lesion-infiltrating TH
cells. n=3–6 mice/group.
(D) Representative flow cytometry plots of IL-4 and IL-10 expression in TH cells, with
cellular density quantified in early stage KPC-OG and KPC mice. n=3–6 mice/group.
(E) Density of TNF-a-expressing IL-17A+ TH and TNF-a-expressing IL-4+ TH measured by
flow cytometry in early stage KPC-OG and KPC mice. n=3–6 mice/group.
(F) Frequency of IFN-g and Tbet expression in KPC or KPC-OG lesion-infiltrating TH
cells. n=3–6 mice/group.
(G) Representative flow plots depicting depletion of FOXP3+ TREGS in blood and
pancreas of KPC-OG mice treated with anti-CD25 antibodies, with quantification of
FOXP3 by immunohistochemistry. n=6–7 mice/group.
(H) Quantification of lesion area in pancreas of early stage KPC-OG mice treated with
anti-CD25 antibodies. n=8–12 mice/group.
(I) Frequency and density of IFN-g-expressing TH cells in lesion-infiltrating TH cells of
KPC-OG pancreas and KPL-OG lung. n=4–6 mice/group.
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(J) Frequency of Tbet, GATA3, and RORgt expression in CD4+ TH cells infiltrating KPLOG early lung and KPC-OG early pancreatic lesions. n=4–6 mice/group.
Unless stated otherwise, data were consistent and pooled across two independent
experiments. Scale bar denotes 500 µm. n.s., not significant; *p < 0.05, **p < 0.01. Error
bar represents SEM. For comparisons between two groups, Student’s two-tailed t-test
was used.
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Figure 2.7 – cDCs are fewer and less functional at peripheral priming in PDAC
compared to lung cancer
(A) Heat map depicting the mean density (log-scale) of major myeloid cell infiltrates in
late stage pancreatic and lung disease. n=5–10 mice/group.
(B) Comparison of CD103+ cDC1 and CD11b+ cDC2 density in (LEFT) early stage
pancreas with lung lesions, and (RIGHT) in late stage pancreatic tumors with lung
tumors. n=5–10 mice/group.
(C) Comparison of migratory CD103+ DC1 and CD11b+ DC2 density in respective
draining lymph nodes of late stage KPC-OG pancreatic tumors with KPL-OG lung
tumors. n=7 mice/group.
(D) Immunohistochemistry 1X images of tumor CK7/19 expression, and magnified
images of Zbtb46GFP+ (pink) cDCs in late stage KPC or KPL bone marrow
chimeras. RIGHT: quantification of Zbtb46GFP+ cDC density in non-tumor tissue
(WT) and late stage tumor. FAR RIGHT: quantification of Snx22 GFP+ Batf3dependent cDC1 density in non-tumor tissue (WT) and late stage tumor. n=4–6
mice/group.
(E) Frequency distribution of Zbtb46 GFP + cDC and Snx22GFP+ Batf3-dependent cDC1
proximity to nearest CK7/19+ lesion. n=3–5 mice/group.
(F) Correlation of cDC1 density (log-scale) with intratumoral OVA-specific CD8+ T cell
density (log-scale) across tissue and stage. RIGHT: quantification of OVA-specific
CD8+ T cell density in early and late stage tumors. n=5–8 mice/group.
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(G) Phenograph of CD45+ immune cell infiltrate from human PDAC patient samples
pooled as part of CyTOF analyses, with quantification of individual cellular fractions
(log-scale). n=11.
(H) Z–normalized cDC1 infiltration score between pancreatic (PAAD, n=177) and lung
(LUAD, n=230) adenocarcinoma based on conserved cDC1-associated gene
signature.
(I) Representative histogram of ZsGreen antigen-uptake by migratory CD103+ cDC1s
and CD11b+ cDC2s found in respective draining lymph nodes of KPC-Z or KPL-Z
tumors at denoted time points. RIGHT: percentage of migratory cDC subsets that
have taken up ZsGreen antigen in respective draining lymph nodes at denoted time
points. n=3–4 mice/group.
(J) Density of OVA-specific CD8+ T cells in draining lymph nodes of early stage tissues.
n=5–8 mice/group.
Data were consistent across two independent experiments, except in (A), (B), and (F)–
(H) where they were pooled across multiple experiments. Scale bar denotes 100 µm.
n.s., not significant; *p < 0.05, **p < 0.01. Error bar represents SEM. For comparisons
between any two groups, Student’s two-tailed t-test was used. Frequency distributions
were

compared

using

the

non-parametric
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Kolmogorov-Smirnov

test.
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Figure 2.8 – cDCs are fewer and less functional at peripheral priming in PDAC
compared to lung cancer, Related to Figure 2.7
(A) Gating strategy for major myeloid and DC populations in pancreas, lung and draining
lymph nodes.
(B) Heat map depicting the mean density (log-scale) of major myeloid cell infiltrates in
pancreatic and lung lesions at early stages. n=5–10 mice/group.
(C) Comparison of resident CD8+ DC1 and CD11b+ DC2 density in respective draining
lymph nodes of end stage pancreatic tumors with lung tumors. n=7 mice/group.
(D) Representative flow plots of CD11c+MHCII+CD24mid-hi cDC cells in Zbtb46GFP+ and
Snx22GFP+ BM-chimeras. Grey contours denote parental cDC gating, and red or
pink contours denote GFP+ labeled population in KPC or KPL tissue respectively.
Numbers denote percentage of cDC gate (for Zbtb46GFP column) and percentage
of CD103+XCR1+ cDC1 gate (for Snx22GFP column).
(E) Mean fluorescence intensities of co-stimulatory and co-inhibitory surface markers on
tumor-infiltrating cDC1 and cDC2 populations in endstage KPC or KPL mice. n=3–6
mice/group.
(F) Ex vivo T cell activation (calcium signaling) over the first hour of co-culturing naïve
OT-I CD8+ T cells with SIINFEKL-loaded cDC1s or OT-II naïve CD4+ T cells with
ISQAVHAAHAEINEAGR-loaded cDC2s from endstage KPC or KPL tumors. Inset
denotes elispot for T cell IFN-g production at end of co-culture. Representative of 2
independent experiments.
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(G) Density of tumoral cDC1s and CD8+ T cells measured by flow cytometry in early
stage KPL-OG mice reconstituted with Batf3-/- or WT bone marrow prior to tumor
initiation. n=4 mice/group.
(H) Representative gross images of ZsGreen expression in early KPC-ZsG pancreas
and KPL-ZsG lung. RIGHT: percentage of tumor-infiltrative cDC subsets and TAMs
that have taken up ZsGreen antigen at late stage. n=3–4 mice/group.
n.s., not significant; *p < 0.05, **p < 0.01. Error bar represents SEM. For comparisons
between any two groups, Student’s two-tailed t-test was used.
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Figure 2.9 – Mobilizing cDCs into early pancreatic lesions can reverse fibroinflammatory responses
(A) Schematic of Flt3L administration in KPC-OG mice (starting at P30), with
quantification of CD103+ cDC1 and CD11b+ cDC2 density in early stage pancreas of
KPC-OG mice either treated or not with Flt3L and control KPC mice. n=5–6
mice/group.
(B) Representative H&E images of early stage KPC-OG mice either treated or not with
Flt3L, with quantification of lesion area. n=8–12 mice/group.
(C) Sirius Red staining with quantification in early stage KPC-OG mice either treated or
not with Flt3L. n=8–12 mice/group.
(D) aSMA staining with quantification in early stage KPC-OG mice either treated or not
with Flt3L. n=8–12 mice/group.
(E) Cellular density of RORgt

+

TH17 and GATA3+ TH2 cells quantified in early stage

KPC-OG mice either treated or not with Flt3L. n=3–6 mice/group.
(F) Representative flow cytometry plots of IL-17A and TNF-a expression in TH cells of
early stage KPC-OG mice either treated or not with Flt3L, with cellular density of IL17A+ and TNF-a+ IL-17A+ TH cells quantified. n=3–6 mice/group.
(G) Representative immunohistochemistry images of CD8+ T cells (brown) and CK19+
tumor lesions (pink) in early stage KPC-OG mice either treated or not with Flt3L, with
CD8+ T cell density within 30 µm of lesions quantified. n=6 mice/group.
(H) Frequency distribution of CD8+ T cell proximity to nearest CK19+ lesion in early
stage KPC-OG mice either treated or not with Flt3L. n=6 mice/group.
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(I) Density of IFN-g+ TNF-a+ cytotoxic CD8+ T cell density measured by flow cytometry
in early stage KPC-OG mice either treated or not with Flt3L. n=6 mice/group.
(J) Representative H&E images of early stage KPC-OG mice treated with Flt3L and
anti-CD8 or anti-IFN-g depletion antibodies, with quantification of lesion area. n=7–
12 mice/group.
Data were consistent across two independent experiments, except in (B)–(D) and (H)–
(J) where they were pooled across multiple experiments. Scale bar denotes 500 µm in
(B), (C), (D), and (J); bar denotes 100 µm in (G). n.s., not significant; *p < 0.05, **p <
0.01. Error bar represents SEM. For comparisons between any two groups, Student’s
two-tailed t-test was used. Frequency distributions were compared using the nonparametric Kolmogorov-Smirnov test.
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Figure 2.10 – Mobilizing cDCs into early pancreatic lesions can reverse fibroinflammatory responses, Related to Figure 2.9
(A) Lesion grades for early stage KPC-OG mice either treated or not with Flt3L. n=8–12
mice/group.
(B) Frequency of IL-17A and RORgt expression in lesion-infiltrating TH cells of KPC-OG
mice either treated or not with Flt3L. n=3–6 mice/group.
(C) Frequency of GATA3 skew in lesion-infiltrating TH cells of KPC-OG mice either
treated or not with Flt3L. n=3–6 mice/group.
(D) Frequency of IFN-g expression in lesion-infiltrating TH cells of KPC-OG mice either
treated or not with Flt3L. n=3–6 mice/group.
(E) Cellular density of TNF-a+ TH cells in early stage KPC-OG mice either treated or not
with Flt3L. n=3–6 mice/group.
(F) Frequency of ki67 expression in lesion-infiltrating CD8+ CTL cells of KPC-OG mice
either treated or not with Flt3L. n=3–6 mice/group.
(G) Representative immunofluorescence images and quantification of GFP expression
(green) in CK19+ lesions (red) of early stage KPC-OG tumors treated as denoted.
GFP-edited lesions are demarcated by yellow line. n=5 mice/group.
(H) Representative images of cleaved caspase 3 (CC3) staining in early stage KPC-OG
mice treated with Flt3L and anti-CD8 depletion antibodies, with quantification of
CC3+ tumor cells restricted to lesion area. n=8–9 mice/group.
Data were consistent and pooled across two independent experiments. Scale bar
denotes 100 µm. n.s., not significant; *p < 0.05, **p < 0.01. Error bar represents SEM.
For comparisons between two groups, Student’s two-tailed t-test was used.
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Figure 2.11 – Enhancing cDC infiltration and activation in established PDAC leads
to disease stabilization
(A) Schematic of Flt3L administration in ultrasound-diagnosed KPPC-OG mice. n=5–8
mice/group.
(B) Density of (LEFT) CD103+ cDC1s, CD11b+ cDC2s in tumors of KPPC-OG mice
treated with Flt3L and (RIGHT) migratory cDC1, cDC2 populations in respective
dLNs. n=5–8 mice/group.
(C) Density of CD8+ T cells, CD4+ TH cells and frequency of CD4+ TREG in tumors of
KPPC-OG mice treated with Flt3L. n=5–8 mice/group.
(D) Density of CD103+ cDC1s, CD11b+ cDC2s in tumors of KPPC-OG mice treated in
combination as described. n=7–8 mice/group.
(E) Density of CD8+ T cells and CD4+ TH cells and frequency of CD4+ TREGS in tumors of
KPPC-OG mice treated as described. n=7–8 mice/group.
(F) Density of OVA-specific CD8+ T cells in tumors of treated KPPC-OG mice. n=5–8
mice/group.
(G) Representative immunohistochemistry images of CD8+ T cells (brown) and CK19+
tumor lesions (pink) in KPPC-OG mice treated as denoted. RIGHT: quantification of
cumulative CD8+ T cell density within 50 µm of lesions. n=5–8 mice/group.
(H) Density of tumor-infiltrating NK cells, NKT cells and gd T cells in treated KPPC-OG
mice. n=5–8 mice/group.
(I) Representative flow histogram indicating ZsGreen antigen-uptake by migratory
CD103+ cDC1s in draining lymph node of KPPC-Z treated as denoted. RIGHT:
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quantification of absolute number of migratory DC subsets that have ZsGreen
antigen. n=3–4 mice/group.
(J) Density of OVA-specific CD8+ T cell in draining lymph node of treated KPPC-OG
mice. n=5–8 mice/group.
(K) Tumor growth quantified by ultrasound measurements over 2 weeks of treatment.
RIGHT: Individual traces of untreated and anti-CD40 plus Flt3L combination
treatment cohorts. n=5–8 mice/group.
(L) Representative Masson’s trichrome staining with quantification in KPPC-OG mice
treated as denoted. n=5–8 mice/group.
(M)Representative a-SMA staining with quantification in KPPC-OG mice treated as
denoted. n=5–8 mice/group.
Data were pooled across multiple independent experiments for all treatments. Scale bar
denotes 100 µm in (G); bar denotes 500 µm in (L) and (M). n.s., not significant; *p <
0.05, **p < 0.01. Statistics with respect to untreated group, unless noted. Error bar
represents SEM. For comparisons between any two groups, Student’s two-tailed t-test
was used.
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Figure 2.12 – Enhancing cDC infiltration and activation in established PDAC leads
to disease stabilization, Related to Figure 2.11
(A) Mean fluorescence intensities of co-stimulatory surface markers on tumor-infiltrating
cDC1 and cDC2 populations in mice treated as denoted. n=5–8 mice/group.
(B) Gating strategy for major pre-DC populations, monocytes and granulocytes in blood.
(C) Abundance of pre-cDC1, pre-cDC2, and Ly6C+ monocytes in blood of mice 9 days
after treatment as denoted. n=4 mice/group.
(D) Density of tumor-infiltrating B cells and TAMs in KPPC-OG mice treated as denoted.
n=5–8 mice/group.
(E) Representative immunofluorescence images and quantification of GFP expression
(green) in CK19+ lesions (red) of KPPC-OG tumors treated as denoted. GFP-edited
lesions are demarcated by yellow line. n=8 mice/group.
(F) Density of tumor-infiltrating immune cells in KPPC (non-OVA) mice treated with antiCD40 and Flt3L. n=7–9 mice/group.
(G) Tumor growth in KPPC mice quantified by ultrasound measurements over 2 weeks
of treatment. RIGHT: Individual traces of untreated and anti-CD40 plus Flt3L
combination treatment cohorts. n=7 mice/group.
(H) Tumor growth in KPPC mice treated as denoted with or without T cell depletion,
quantified by ultrasound measurements over 2 weeks of treatment. n=8 mice/group.
(I) Percentage change in tumor volume (day 0 to day 7) of Kras-Ink orthotopic tumors
after treatments. n=11–15 mice/group.
(J) Representative Podoplanin immunohistochemistry with quantification in KPPC-OG
mice treated as denoted. n=5–8 mice/group.
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(K) Representative MMP9 immunohistochemistry with quantification in KPPC-OG mice
treated as denoted. n=8 mice/group.
Data were pooled across multiple independent experiments for all treatments. Scale bar
denotes 100 µm in (E); bar denotes 500 µm in (J) and (K).. n.s., not significant; *p <
0.05, **p < 0.01. Error bar represents SEM. For comparisons between any two groups,
Student’s two-tailed t-test was used.
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Figure 2.13 – cDC-directed therapy renders PDAC responsive to radiation therapy
(A) Dosage schema for administration of radiation (RT) in KPPC-OG mice treated with
Flt3L and anti-CD40 upon ultrasound-based tumor diagnosis at day 0.
(B) KPPC-OG tumor growth kinetics quantified by ultrasound measurements over 2
weeks of treatment. n=8 mice/group.
(C) Percentage change in KPPC-OG tumor volume after RT (day 7 to day 14) with
representative images. n=8 mice/group.
(D) Dosage schema for administration of radiation (RT) in orthotopic Kras-Ink model
treated with Flt3L and anti-CD40 upon tumor diagnosis.
(E) Kras-Ink tumor growth kinetics quantified by ultrasound measurements over 2 weeks
of treatment. n=8 mice/group.
(F) Percentage change in Kras-Ink tumor volume after RT (day 6 to day 13). n=8
mice/group.
(G) Kaplan-Meier survival curve for Kras-Ink orthotopic tumor-bearing mice undergoing
RT alone or RT in conjunction with Flt3L and anti-CD40. n=9–14 mice/group.
(H) Dosage schema for administration of radiation (RT) in KPPC mice treated with Flt3L
and anti-CD40 upon ultrasound-based tumor diagnosis at day 0.
(I) KPPC tumor growth kinetics quantified by ultrasound measurements over 5 weeks
since starting treatment. n=8 mice/group.
(J) Kaplan-Meier survival curve for KPPC mice undergoing RT alone or RT in
conjunction with Flt3L and anti-CD40. n=10–16 mice/group.
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Data were pooled across multiple experiments for (A)–(C), (H)–(J), and representative
of two independent experiments for (D)–(G). n.s., not significant; *p < 0.05, **p < 0.01.
Error bar represents SEM. For comparisons between any two groups, Student’s twotailed T-test was used.
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Figure 2.14 – cDC-directed therapy renders PDAC responsive to radiation
therapy, Related to Figure 2.13
(A) Kras-Ink orthotopic tumor burden at end point as measured by ultrasound. n=9–14
mice/group.
(B) Kras-Ink orthotopic tumor weight at end point after immune checkpoint blockade in
conjunction with anti-CD40 and Flt3L. n=11–15 mice/group.
n.s., not significant; *p < 0.05, **p < 0.01. Error bar represents SEM. For comparisons
between any two groups, Student’s two-tailed t-test was used.
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2.5 Tables
Table 2.1 – Enriched KEGG pathway terms after WGCNA clustering
GO KEGG
TERM

Description

Count
(/1312)

mmu04510
mmu05205
mmu05200
mmu04512
mmu04810
mmu04151
mmu04010
mmu04670
mmu05418
mmu04015

Focal adhesion
Proteoglycans in cancer
Pathways in cancer
ECM-receptor interaction
Regulation of actin cytoskeleton
PI3K-Akt signaling pathway
MAPK signaling pathway
Leukocyte transendothelial migration
Fluid shear stress and atherosclerosis
Rap1 signaling pathway

mmu04610
mmu05132

(log 10) p
value

85
84
157
42
77
103
88
45
52
67

-16.76
-15.62
-13.97
-10.93
-10.68
-8.00
-7.66
-7.34
-7.33
-7.05

Complement and coagulation cascades
Salmonella infection

37
34

-7.01
-6.90

mmu05133
mmu04933

Pertussis
AGE-RAGE signaling pathway

33
39

-6.66
-6.43

mmu04360
mmu05152

Axon guidance
Tuberculosis

57
57

-6.32
-6.05

mmu05222
mmu04380
mmu04145
mmu05165
mmu04014
mmu04668

Small cell lung cancer
Osteoclast differentiation
Phagosome
Human papillomavirus infection
Ras signaling pathway
TNF signaling pathway

36
44
56
96
66
38

-6.01
-5.54
-5.44
-5.44
-4.97
-4.85

mmu05217
mmu04530
mmu05140
mmu05144

Basal cell carcinoma
Tight junction
Leishmaniasis
Malaria

26
51
27
22

-4.81
-4.81
-4.81
-4.81

mmu05226
mmu04611
mmu01522
mmu05146

Gastric cancer
Platelet activation
Endocrine resistance
Amoebiasis

47
41
33
36

-4.81
-4.81
-4.56
-4.51

mmu04912
mmu05100
mmu04540

GnRH signaling pathway
Bacterial invasion of epithelial cells
Gap junction

32
28
31

-4.48
-4.48
-4.48
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mmu04666
mmu04210
mmu05224
mmu04921
mmu04926
mmu05414
mmu04270
mmu04062
mmu05225
mmu05145
mmu04072
mmu05412
mmu05150
mmu04974
mmu04621
mmu04550
mmu05212
mmu05214
mmu05410
mmu04310
mmu05220
mmu04520
mmu04390
mmu04625
mmu04972
mmu05230
mmu00600

Fc gamma R-mediated phagocytosis
Apoptosis
Breast cancer
Oxytocin signaling pathway
Relaxin signaling pathway
Dilated cardiomyopathy (DCM)
Vascular smooth muscle contraction
Chemokine signaling pathway
Hepatocellular carcinoma
Toxoplasmosis
Phospholipase D signaling pathway
Arrhythmogenic right ventricular cardiomyopathy
Staphylococcus aureus infection
Protein digestion and absorption
NOD-like receptor signaling pathway
Pathways regulating pluripotency of stem cells
Pancreatic cancer
Glioma
Hypertrophic cardiomyopathy (HCM)
Wnt signaling pathway
Chronic myeloid leukemia
Adherens junction
Hippo signaling pathway
C-type lectin receptor signaling pathway
Pancreatic secretion
Central carbon metabolism in cancer
Sphingolipid metabolism

31
42
44
45
40
30
39
54
48
34
42
25
21
29
46
39
25
24
27
41
25
24
42
33
31
22
18

-4.37
-4.18
-4.01
-3.92
-3.88
-3.74
-3.69
-3.68
-3.66
-3.61
-3.39
-3.37
-3.35
-3.28
-3.27
-3.14
-3.09
-3.07
-3.06
-3.05
-3.02
-3.00
-2.99
-2.99
-2.99
-2.98
-2.95

mmu04916
mmu05216
mmu04261
mmu05166

Melanogenesis
Thyroid cancer
Adrenergic signaling in cardiomyocytes
Human T-cell leukemia virus 1 infection

30
15
40
67

-2.89
-2.88
-2.87
-2.87

mmu04915
mmu04024
mmu05210
mmu05020

Estrogen signaling pathway
cAMP signaling pathway
Colorectal cancer
Prion diseases

37
50
27
14

-2.87
-2.82
-2.81
-2.81

mmu04022
mmu05164
mmu05202
mmu04071

cGMP-PKG signaling pathway
Influenza A
Transcriptional misregulation in cancer
Sphingolipid signaling pathway

44
44
47
34

-2.81
-2.81
-2.80
-2.69
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mmu04970
mmu04340
mmu05142
mmu04971
mmu04350
mmu05219
mmu01521
mmu04620
mmu04392
mmu05218
mmu04514
mmu00480
mmu05323
mmu04722
mmu05223
mmu00512
mmu05134
mmu05213
mmu05167
mmu04713
mmu04934
mmu04976
mmu05163
mmu04924
mmu01524
mmu00603
mmu05032

Salivary secretion
Hedgehog signaling pathway
Chagas disease (American trypanosomiasis)
Gastric acid secretion
TGF-beta signaling pathway
Bladder cancer
EGFR tyrosine kinase inhibitor resistance
Toll-like receptor signaling pathway
Hippo signaling pathway - multiple species
Melanoma
Cell adhesion molecules (CAMs)
Glutathione metabolism
Rheumatoid arthritis
Neurotrophin signaling pathway
Non-small cell lung cancer
Mucin type O-glycan biosynthesis
Legionellosis
Endometrial cancer
Kaposi sarcoma-associated herpesvirus
Circadian entrainment
Cushing syndrome
Bile secretion
Human cytomegalovirus infection
Renin secretion
Platinum drug resistance
Glycosphingolipid biosynthesis
Morphine addiction

24
16
29
23
25
15
24
28
11
22
42
20
24
32
20
11
18
18
50
26
38
20
56
20
21
7
24

-2.54
-2.53
-2.53
-2.52
-2.44
-2.42
-2.40
-2.36
-2.36
-2.33
-2.26
-2.26
-2.19
-2.19
-2.10
-2.09
-2.02
-2.02
-1.97
-1.83
-1.83
-1.73
-1.71
-1.66
-1.65
-1.64
-1.64

mmu04020
mmu04978
mmu05215
mmu04144

Calcium signaling pathway
Mineral absorption
Prostate cancer
Endocytosis

42
14
25
58

-1.64
-1.64
-1.64
-1.63

mmu04918
mmu05321
mmu05221
mmu05160

Thyroid hormone synthesis
Inflammatory bowel disease (IBD)
Acute myeloid leukemia
Hepatitis C

20
17
19
32

-1.63
-1.62
-1.58
-1.56

mmu04060
mmu04066
mmu04657
mmu04928

Cytokine-cytokine receptor interaction
HIF-1 signaling pathway
IL-17 signaling pathway
Parathyroid hormone synthesis, secretion

62
26
23
26

-1.51
-1.50
-1.44
-1.40
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mmu04659
mmu00051
mmu04064

Th17 cell differentiation
Fructose and mannose metabolism
NF-kappa B signaling pathway

84

25
11
25

-1.40
-1.37
-1.30

Table 2.2 – Enriched Biological Process (BP) terms after REVIGO
GO BP
TERM
GO:0048514
GO:0006954
GO:0001817
GO:0030335
GO:0042330
GO:0031347
GO:0006935
GO:0097435
GO:0031589
GO:0030198
GO:0043062
GO:0002443
GO:0050900
GO:0050778

Description

GO:0009611
GO:0010810
GO:0042060
GO:0043410

response to wounding
regulation of cell-substrate adhesion
wound healing
positive regulation of MAPK cascade

33.89
30.33
29.59
27.58

-6.62
-6.17
-6.18
-5.98

GO:0032103

25.64

-5.71

GO:0031349
GO:0030036
GO:0007159
GO:0002274
GO:0002250
GO:0001667

positive regulation of response to external
stimulus
positive regulation of defense response
actin cytoskeleton organization
leukocyte cell-cell adhesion
myeloid leukocyte activation
adaptive immune response
ameboidal-type cell migration

25.38
25.20
25.12
23.41
21.97
19.23

-5.70
-5.74
-5.68
-5.40
-5.30
-4.94

GO:0002521
GO:0090130
GO:0010631

leukocyte differentiation
tissue migration
epithelial cell migration

17.80
17.42
17.40

-4.74
-4.65
-4.64

blood vessel morphogenesis
inflammatory response
regulation of cytokine production
positive regulation of cell migration
taxis
regulation of defense response
chemotaxis
supramolecular fiber organization
cell-substrate adhesion
extracellular matrix organization
extracellular structure organization
leukocyte mediated immunity
leukocyte migration
positive regulation of immune response
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Fold
(log 10)
change
p value
105.49
-10.80
99.44
-10.56
76.17
-9.51
72.07
-9.27
52.91
-8.13
52.03
-8.09
51.20
-8.02
49.16
-7.90
47.94
-7.72
44.72
-7.39
44.72
-7.39
37.74
-6.91
35.55
-6.72
34.94
-6.73

Table 2.3 – KEY RESOURCES
REAGENT or RESOURCE

SOURCE

IDENTIFIER

anti-mouse CD45 (30-F11)

eBioscience

RRID: AB_469625

anti-mouse CD3e (145-2C11)

eBioscience

RRID: AB_469315

anti-mouse CD19 (eBio1D3)

eBioscience

RRID: AB_1659676

anti-mouse CD11b (M1/70)

eBioscience

RRID: AB_657585

anti-mouse MHCII (I-A/I-E) (M5/114.15.2)

eBioscience

RRID: AB_1272204

anti-mouse Ly6G (1A8)

BioLegend

RRID: AB_1186104

anti-mouse Ly6C (HK1.4)

eBioscience

RRID: AB_1518762

anti-mouse F4/80 (BM8)

eBioscience

RRID: AB_468798

anti-mouse CD45 (30-F11)

BD Biosciences

RRID: AB_2716861

anti-mouse CD3e (145-2C11)

eBioscience

RRID: AB_1107000

anti-mouse CD3e (145-2C11)

BD Biosciences

RRID: AB_2687954

anti-mouse CD11c (N418)

eBioscience

RRID: AB_1548652

anti-mouse CD24 (30-F1)

eBioscience

RRID: AB_464985

anti-mouse CD24 (M1/69)

eBioscience

RRID: AB_464988

anti-mouse CD103 (2E7)

BioLegend

RRID: AB_2562713

anti-mouse XCR1 (ZET)

BioLegend

RRID: AB_2565230

anti-mouse CD8a (53-6.7)

BD Biosciences

RRID: AB_2732919

anti-mouse CD8a (53-6.7)

BD Biosciences

RRID: AB_11152075

anti-mouse CD4 (RM4-4)

eBioscience

RRID: AB_464900

anti-mouse CD62L (MEL-14)

BioLegend

RRID: AB_11125577

anti-mouse CD44 (IM7)

eBioscience

RRID: AB_1272246

anti-mouse PD1 (J43)

eBioscience

RRID: AB_466295

anti-mouse TIGIT (1G9)

BD Biosciences

RRID: AB_2742062

anti-mouse TIM3 (RMT3-23)

Biolegend

RRID: AB_2571932

ANTIBODIES
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anti-mouse CD40L (MR1)

Biolegend

RRID: AB_2563493

anti-mouse ICOS (15F9)

BioLegend

RRID: AB_313337

anti-mouse CD22 (OX-97)

BioLegend

RRID: AB_2244414

anti-mouse γδ TCR (eBioGL3)

eBioscience

RRID: AB_465934

anti-mouse CD49b (DX5)

eBioscience

RRID: AB_469485

anti-mouse NK1.1 (PK136)

BD Biosciences

RRID: AB_2728688

anti-mouse Ki-67 (SolA15)

eBioscience

RRID: AB_2574235

anti-mouse FOXP3 (FJK-16s)

eBioscience

RRID: AB_11218094

anti-mouse CD16/32 (93)

eBioscience

RRID: AB_467133

anti-mouse F4/80 (BM8)

BioLegend

RRID: AB_2564589

anti-mouse MHCI (Kd/Dd) (34-1-2S)

eBioscience

RRID: AB_465358

anti-mouse B220 (RA3-6B2)

BioLegend

RRID: AB_312997

anti-mouse CD80 (16-10A1)

eBioscience

RRID: AB_468774

anti-mouse CD86 (GL1)

eBioscience

RRID: AB_469419

anti-mouse CD107a (1D4B)

BD Biosciences

RRID: AB_2739285

anti-mouse SIINFEKL Dextramer (N/A)

Immudex

Cat# JD2163

anti-mouse IL-4 (11B11)

BioLegend

RRID: AB_315320

anti-mouse IL-10 (JES5-16E3)

BioLegend

RRID: AB_2563240

anti-mouse IFN-γ (XMG1.2)

BioLegend

RRID: AB_315402

anti-mouse TNFa (MP6-XT22)

eBioscience

RRID: AB_10670212

anti-mouse IL-17A (eBio17B7)

eBioscience

RRID: AB_10732356

anti-mouse Tbet (eBio4B10)

eBioscience

RRID: AB_11042699

anti-mouse ROR-gamma T (Q31-378)

BD Biosciences

RRID: AB_2651150

anti-mouse EOMES (Dan11mag)

Ebioscience

RRID: AB_2573454

anti-mouse Granzyme B (GB11)

BD Biosciences

RRID: AB_2738174

anti-mouse MHCII (I-A/I-E) (M5/114.15.2)

Biolegend

RRID: AB_313322

anti-mouse CD86 (B7-2) (GL1)

eBioscience

RRID: AB_469419
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anti-mouse CD252 (OX40L) (RM134L)

Biolegend

RRID: AB_313404

anti-mouse CD274 (PD-L1) (MIH5)

eBioscience

RRID: AB_466089

anti-mouse CD137L (4-1BBL) (TKS-1)

Biolegend

RRID: AB_2256408

anti-mouse IgGa, K (MOPC-173)

Biolegend

RRID: AB_326480

anti-mouse IgG1, K (eBRG1)

Ebioscience

RRID: AB_470009

anti-mouse IgG1, K (RTK2071)

Ebioscience

RRID: AB_326518

anti-mouse IgG1, K (RTK2071)

Ebioscience

RRID: AB_326514

anti-mouse CD40 (FGK4.5)

BioXCell

RRID: AB_1107647

anti-mouse CD4 (GK1.5)

BioXCell

RRID: AB_1107636

anti-mouse CD8a (2.43)

BioXCell

RRID: AB_1125541

anti-mouse CD19 (1D3)

BioXCell

RRID: AB_10949187

anti-mouse B220 (TIB-146)

BioXCell

RRID: AB_1107651

anti-mouse IL-17A (17F3)

BioXCell

RRID: AB_10950102

anti-mouse IL-17F (MM17F8F5.1A9)

BioXCell

RRID: AB_2715461

anti-mouse IFN-γ (XMG1.2)

BioXCell

RRID: AB_1107694

anti-mouse CD25 (IL-2Ra; PC-61.5.3)

BioXCell

RRID: AB_1107619

anti-mouse IgG2a (2A3)

BioXCell

RRID: AB_1107769

anti-mouse IgG1 (MOPC-21)

BioXCell

RRID: AB_1107784

anti-mouse IgG2b (LTF-2)

BioXCell

RRID: AB_1107780

anti-mouse PD1 (RMP1-14)

BioXCell

RRID: AB_10949053

anti-mouse CTLA4 (UC10-4F10-11)

BioXCell

RRID: AB_1107598

anti-mouse F4/80 biotinylated (BM8)

Ebioscience

RRID: AB_466657

anti-mouse GR-1 biotinylated (RB6-8C5)

Abcam

RRID: AB_470753

anti-mouse CD8a biotinylated (53-6.7)

Ebioscience

RRID: AB_466346

anti-mouse CD4 biotinylated (GK1.5)

Ebioscience

RRID: AB_466325

anti-mouse FOXP3 (FJK-16s)

Ebioscience

RRID: AB_467576

anti-mouse B220 (RA3-6B2)

BD Biosciences

RRID: AB_396673
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anti-mouse Pan-cytokeratin (Poly)

Cell Signaling

RRID: AB_836890

anti-mouse alpha-SMA (Poly)

Abcam

RRID: AB_2223021

anti-mouse Podoplanin (8.1.1)

Biolegend

RRID: AB_1089187

anti-mouse ki67 (Poly)

Abcam

RRID: AB_443209

anti-mouse Sox2 (Poly)

Cell Signaling

RRID: AB_823640

anti-mouse Cytokeratin 19 (TROMA-III)

DSHB

RRID: AB_2133570

anti-mouse Cytokeratin 17/19 (D4G2)

Cell Signaling

RRID: AB_2797912

anti-mouse GFP (D5.1)

Cell Signaling

RRID: AB_1196615

anti-mouse TTF1 (Nkx2.1) (EP1584Y)

Abcam

RRID: AB_1310784

anti-mouse p-ERK1/2 T202/204 (D13.14.4E)

Cell Signaling

RRID: AB_2315112

anti-mouse p-STAT3 Y705 (D3A7)

Cell Signaling

RRID: AB_2491009

anti-mouse p-EGFR Y1068 (EP774Y)

Abcam

RRID: AB_732110

anti-mouse MMP9 (Poly)

Abcam

RRID: AB_776512

anti-mouse Ovalbumin (Poly)

Thermo Fisher

RRID: AB_2539921

anti-mouse beta-actin (13E5)

Cell Signaling

RRID: AB_2223172

anti-human CD11b (ICRF44)

Fluidigm

#3209003B

anti-human CD11c (Bu15)

Fluidigm

#3159001B

anti-human CD14 (M5E2)

Fluidigm

#3160001B

anti-human CD141 (1A4)

Fluidigm

#3173002B

anti-human CD15 (W6D3)

Fluidigm

#3164001B

anti-human CD16 (3G8)

Fluidigm

#3148004B

anti-human CD163 (GHI/61)

Fluidigm

#3154007B

anti-human CD19 (HIB19)

Fluidigm

#3142001B

anti-human CD192 (CCR2) (K036C2)

Fluidigm

#3153023B

anti-human CD1c (L161)

BioLegend

#331502

anti-human CD20 (2H7)

Fluidigm

#3147001B

anti-human CD206 (MMR) (15-2)

Fluidigm

#3168008B
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anti-human CD24 (ML5)

Fluidigm

#3166007B

anti-human CD3 (UCHT1)

BioLegend

#300402

anti-human CD32 (FUN-2)

Fluidigm

#3169020B

anti-human CD34 (581)

Fluidigm

#3149013B

anti-human CD38 (HIT2)

Fluidigm

#3167001B

anti-human CD40 (5C3)

Fluidigm

#3165005B

anti-human CD45 (HI30)

Fluidigm

#3089003B

anti-human CD54 (HA58)

Fluidigm

#3170014B

anti-human CD56 (NCAM16.2)

Fluidigm

#3176008B

anti-human CD64 (10.1)

Fluidigm

#3146006B

anti-human CD68 (Y1/82A)

Fluidigm

#3171011B

anti-human CD80 (2D10.4)

Fluidigm

#3162010B

anti-human CD81 (5A6)

Fluidigm

#3145007B

anti-human CD82 (ASL-24)

Fluidigm

#3158025B

anti-human CD86 (IT2.2)

Fluidigm

#3150020B

anti-human CX3CR1 (2A9-1)

Fluidigm

#3172017B

anti-human CXCR4 (12G5)

Fluidigm

#3175001B

anti-human HLA-DR (L243)

Fluidigm

#3174001B

anti-human Ki-67 (B56)

Fluidigm

#3161007B

U of Iowa

#VVC-UofIowa-5

Human PDAC Samples

Washington
University

IRB #201704078

Cultrex Basement membrane extract, Pathclear

Trevigen

#3432-001-01

BACTERIAL AND VIRUS STRAINS
Ad5CMVCre
BIOLOGICAL SAMPLES

CHEMICALS, PEPTIDES, AND RECOMBINANT PROTEINS
Doxycycline hyclate

Sigma-Aldrich
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#D9891

SIINFEKL peptide (OVA 257-264)

Sigma-Aldrich

#S7951

ISQ peptide (OVA 323-339)

Invivogen

#vac-isq

Endo-free Ovalbumin

Invivogen

#vac-pova-100

PolyI:C (HMW)

Invivogen

#tlrl-pic-5

Flt3L (CDX-301)

Celldex

N/A

STING agonist (ML-RR-S2 CDA; ADU-S100)

MedChemExpress

#HY-12885B

Recombinant mouse IL-2

Peprotech

#212-12-20UG

Fluo4-AM calcium indicator

Thermo Fisher

#F14201

Collagenase A

Sigma/Roche

#10103586001

DNAse I

Sigma

#11284932001

Cell Stimulation cocktail (PMA/Iono)

Ebioscience

#00-4970-93

Brefeldin A

Biolegend

#420601

Monensin

Biolegend

#420701

Total IgG (mouse) ELISA kit

Thermo Fisher

#88-50400-22

Anti-Ovalbumin IgG1 (mouse) ELISA kit

Cayman chemicals

#500830

CyQUANT LDH cytotoxicity assay kit

Thermo Fisher

#C20300

E.Z.N.A. Total RNA kit I

Omega

#R6834-02

qScript cDNA Supermix kit

Quantabio

#95048-500

Taqman Gene Expression Master Mix

Thermo Fisher

#4370074

TSA Fluorescein kit

Perkin-Elmer

#NEL701001KT

TSA Biotin kit

Perkin-Elmer

#NEL700001KT

BOND Polymer Refine Detection kit

Leica

#DS9800

BOND Polymer Refine Red Detection kit

Leica

#DS9390

BOND Intense R Detection kit

Leica

#DS9263

Cytofix kit

BD Bioscience

#554655

Transcription Factor Staining kit

Ebioscience

#00-5523-00

CRITICAL COMMERCIAL ASSAYS
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MACS LS kit

Miltenyi

#130-042-401

KP-OG1; derived from 20 wk-old KPC-OG mouse

Thesis

N/A

KP-OG2; derived from 16-wk old KPC-OG mouse

Thesis

N/A

KPP-OG2; derived from 10-wk old KPPC-OG
mouse

Thesis

N/A

KPC01–03; derived from ~22 wk-old KPC mouse

Thesis

N/A

KI; derived from Kras-Ink mouse

Doug Hanahan,
EPFL

N/A

mouse: B6.Cg-ROSA26tm1(LSL-OG) i.e. R26 tm1(LSL-OG)

Thesis

N/A

mouse: p48-Cre;KrasLSL-G12D;Trp53fl/fl

Hingorani et al.,
2003; Morton et al.,
2010

N/A

mouse: C57BL/6-Tg(Pdx1-Cre/Esr1*)

The Jackson
Laboratory

Stock#024968

mouse: B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze

The Jackson
Laboratory

Stock#007906

mouse: C57BL/6J

The Jackson
Laboratory

Stock#000664

mouse: C57BL/6-Tg(TcraTcrb)1100Mjb/J

The Jackson
Laboratory

Stock#003831

mouse: C57BL/6-Tg(TcraTcrb)425Cbn/J

The Jackson
Laboratory

Stock#004194

mouse: B6.129S6(C)-Zbtb46tm1.1Kmm/J

The Jackson
Laboratory

Stock#027618

mouse: B6.129S6(C)-Snx22tm1.1Kmm/J

Kenneth M. Murphy,
Wash U

N/A

mouse: C57BL/6NCr

Charles River
Laboratories

Strain#556

mouse: FVB/NCr

Charles River
Laboratories

Strain#559

EXPERIMENTAL MODELS: CELL LINES

EXPERIMENTAL MODELS: ORGANISMS/STRAINS
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OLIGONUCLEOTIDES
Primer: ROSA-WT-F1 – 5’ GTT ATC AGT AAG
GGA GCT GCA GTG GAG TAG 3’

Miyazaki et al., 2005

N/A

Primer: ROSA-WT-R1 – 5’ CCG AAA ATC TGT
GGG AAG TCT TGT CCC TCC 3’

Miyazaki et al., 2005

N/A

Primer: ROSA-NEO-R2 – 5’ CGG AGA ACC TGC
GTG CAA TCC ATC TTG TTC 3’

Miyazaki et al., 2005

N/A

Flowjo v10.5

Flowjo, L.L.C.

RRID: SCR_008520

Prism v8.0.1

Graphpad

RRID: SCR_002798

Rstudio v1.1.456

Rstudio, Inc

https://www.rstudio.com
/

REVIGO

revigo.irb.hr

RRID: SCR_005825

Fiji v2.0.0

ImageJ

RRID: SCR_002285

HALO v2.2

Indica Labs

http://www.indicalab.co
m/halo/

cBioportal v2.2.0

MSK Center for Mol
Onc

https://www.cbioportal.o
rg/

ssGSEA v2.0

Broad Institute

http://software.broadins
titute.org/gsea/index.jsp

GENE-E & Morpheus

Broad Institute

https://software.broadin
stitute.org/morpheus/

FACSDiva

BD Biosciences

RRID: SCR_001456

Cytobank Premium

Cytobank, Inc

RRID: SCR_014043

SOFTWARE AND ALGORITHMS
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2.6 Methods
Genetic mice and other models
The OG mouse (R26 tm1(LSL-OG)) was developed at the Washington University Mouse
Embryonic Stem Cell Core modifying a previously published construct (Miyazaki et al.,
2005). Briefly, this includes a Tet-off regulation cassette for expression of full-length
chicken Ovalbumin and IRES-enhanced GFP under Cre-mediated LSL-control and
hCMV1 promoter. Successful chimeras from C57Bl/6J blastocyst injections were
selected for and verified by DNA sequencing across ROSA junction; bred to C57Bl/6J
background and subsequent founder mice were identified via genomic PCR (primers
listed in Table 2.3).
KPC (p48-Cre;KrasLSL-G12D;Trp53fl/+) or KPPC mice (p48-Cre;KrasLSL-G12D;Trp53fl/fl)
used in these studies have been rapidly bred to C57Bl/6J background in our lab using
speed-congenics and further backcrossed >5-times. Independent founder OG lines
were crossed into our in-house KPC background and backcrossed >3-times while
deriving KPC-OG mice (p48-Cre;KrasLSL-G12D;Trp53fl/+;R26tm1(LSL-OG)), KPPC-OG mice
(p48-Cre;KrasLSL-G12D;Trp53fl/fl;R26tm1(LSL-OG)),

or

PC-OG

mice

(p48-

Cre;Trp53fl/fl;R26tm1(LSL-OG)). KP-OG mice (KrasLSL-G12D;Trp53fl/fl;R26tm1(LSL-OG)) were
administered Ad5CMVCre at 6 weeks of age by intratracheal instillation to generate
analogous lung tumors (DuPage et al., 2011). Unless noted otherwise, KPC/KPC-OG
mice were either kept on doxycycline (0.5 mg/ml doxycycline in water, changed every 3
days) or weaned off it at birth and analyzed at experimental timepoints as mentioned.

94

LSL-ZsG mice (B6.Cg-Gt(ROSA)26Sortm6(CAG-ZsGreen1)Hze) were crossed into our inhouse KPC background and backcrossed >3-times while deriving KPC-ZsG mice (p48Cre;KrasLSL-G12D;Trp53fl/+;R26tm1(LSL-ZsG)). KP-ZsG mice (KrasLSL-G12D;Trp53fl/+;R26tm1(LSLZsG)

) were administered Ad5CMVCre at 6 weeks of age by intratracheal instillation to

generate analogous lung tumors. For some studies; tamoxifen-inducible Pdx1-Cre/Esr1*
mice (Gu et al., 2002) were bred with KP-OG mice to generate iKPC-OG mice (Pdx1Cre/Esr1*;KrasLSL-G12D;Trp53fl/fl;R26tm1(LSL-OG)). iKPC-OG and iKPC mice at 5 weeks
were administered tamoxifen for 5 days (2 mg i.p. daily, dissolved in corn oil). Survival
events were scored when mice lost >15% body weight, tumor burden reached >1.8 cm
in diameter, moribund appearance, severe cachexia, or per absolute survival. For all
studies, care was taken to include negative littermates as well as sex- and age-match in
the same experimental setup. KPPC/KPPC-OG mice were enrolled for treatment
studies when first >0.5 cm tumor was detected by biweekly palpation corroborated by
ultrasound measurement. Thereafter, tumor size was assessed weekly by ultrasound
(SonoSite m-Turbo). Survival events were scored when mice lost >15% body weight,
tumor burden reached >1.8 cm in diameter or per absolute survival outcome. Dietgel
was provided for 14-day window immediately following radiation therapy in survival
studies.
OT-I TCR-Tg mice, OT-II TCR-Tg mice, C57Bl/6 and FVB/N mice were obtained
from Jackson or Charles River laboratories. Snx22-GFP and Zbtb46-GFP were
provided kindly by Dr. Kenneth Murphy (Washington University). Snx22-GFP and
Zbtb46-GFP mice were backcrossed >3 times to C57Bl/6 background before being
used. All mice were housed, bred and maintained under specific pathogen-free
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conditions in accordance with NIH-AALAC standards and consistent with Washington
University School of Medicine IACUC regulations (protocol #20160265).
Human subjects
Human PDAC samples were obtained from consenting patients diagnosed at
Washington University. Patients underwent pancreaticoduodenectomy and had not
received neoadjuvant therapy. Washington University Ethics committee approved the
study under IRB protocol #201704078.
Cell lines
Three independent primary cell lines were derived from tumor-bearing female KPC-OG
or KPPC-OG mice (denoted KP-OG1 and KP-OG2 and KPP-OG2), along with three
control KPC-derived lines. We observed similar in vivo and ex vivo results for all OGexpressing cell lines; data from one cell line (KP-OG1) is reported unless noted. KrasInk or KI cells used in certain orthotopic transplant experiments were derived from
Pdx1-Cre;LSL-KrasG12D;Ink/Arffl/fl mice in Dr. Hanahan's laboratory (EPFL, Lausanne).
Cell suspension derived after tumor harvest (detailed below) was plated on collagencoated tissue culture flasks under standard antibiotics. GFP+ tumor cells were sorted on
FACSAria-II (BD Biosciences), and re-plated in complete medium until stable cell lines
were established. All cell lines were cultured in complete medium (DMEM-F12 with 10%
FBS and 1% PenStrep) at 37C and 5%CO2. All cell lines were passaged <6 times and
were tested positive for cytokeratin-19, and negative for smooth muscle actin (SMA)
and vimentin to verify their carcinoma identity and purity. All cell lines were tested
negative for MAP and mycoplasma using 2 independent commercial kits (Sigma).
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Tissue harvest
Mice were euthanized by transcardiac perfusion (insert LV apex, cut RA) using 15 mL of
PBS-heparin under isoflurane anesthesia. For lung studies, mice were euthanized by
lung-specific perfusion (insert RV apex, cut LA) using 10 mL of PBS-heparin under
isoflurane anesthesia. When taken for histology, tumor tissue were equally divided
between 10% neutral-buffered formalin and OCT-based cryopreservation. When taken
for cellular assays, tumor tissue or respective lymph nodes were manually minced and
digested in 20 mL of sterile 1X HBSS (Thermo Fisher) containing 2 mg/mL of
collagenase A (Roche) and 1X DNase I (Sigma) for 30 min at 37C with constant stirring.
Digestion was quenched in 5 mL of sterile fetal bovine serum (FBS, Atlanta Biologicals)
filtered through 40 μm Nylon mesh, pelleted through centrifugation (2000 RPM for 5 min
at 4C), and resuspended in required media/buffer to get single cell suspensions.
Orthotopic implantations
To establish orthotopic models, either 100,000 KI or 200,000 KP-OG cells in 50 μL of
Cultrex (Trevigen) were injected into the pancreas of 8-12-week old sex-matched
FVB/NJ or C57Bl/6-background PC-OG mice as previously described (Kim et al., 2009).
For 5 days prior to implantation of KP-OG cells, recipient mice were kept on 0.5 mg/ml
doxycycline (in water, changed every 3 days) and cells were kept on 1.5 μg/ml
doxycycline (in medium, changed every 3 days). Certain groups were weaned off
doxycycline 3 days post-tumor implant.
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Perinatal and immunotherapeutic neutralizing antibodies
For cellular depletion perinatally, neutralizing IgG antibodies were administered to postpartum dam in KPC-OG breeding cages via i.p. injection to pass onto pups via milk. The
first injection was given to the female on the day of litter. For T cell depletion perinatally,
CD4- or CD8-neutralizing IgG antibodies (anti-mCD4 clone GK1.5; anti-mCD8 clone
2.43, BioXCell) were administered, with 1st injection containing 400 μg and subsequent
injections (every 4 days) containing 200 μg of each IgG. Once pups were 3 weeks old;
individual weaned pups received 200 μg every 4 days, until 6-week timepoints were
reached. Isotype controls with same dosage were administered similarly (rat IgG2b
clone LTF-2, BioXCell). For B cell depletion perinatally, CD19- and B220-neutralizing
IgG antibodies (rat clone 1D3; clone TIB-146, BioXCell) were administered, with 1st
injection containing 900 μg and subsequent injections (every 4 days) containing 450 μg
of each IgG. Once pups were 3 weeks old; individual weaned pups received 300 μg
every 4 days, until 6-week timepoints were reached. Depletion of targeted cell type was
verified both in pancreas and blood by flow cytometry, utilizing staining antibodies of a
different clone (CD4 clone RM4-4; CD8 clone 53-6.7; CD19 clone DK5). For cytokine
depletion regimen, 400 μg each of IL-17A and IL-17F neutralizing antibodies (rat clone
17F3; clone MM17F8F5.1A9, BioXCell) or 250 μg of IFN-g neutralizing antibodies (rat
clone XMG1.2, BioXCell) were similarly administered (every 3-4 days) until 6-week
timepoint was reached.
For immunotherapy regimen, 250 μg of agonist antibodies (anti-mCTLA4 clone
UC10-4F10-11; anti-mPD1 clone RMP1-14; BioXCell) were given by intraperitoneal
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(i.p.) injection; anti-PD1 was given every 3 days and anti-CTLA4 was given every 4
days from beginning of treatment.
Adoptive T cell transfer
Three days prior to adoptive transfer, spleen and inguinal lymph node from OT-I Tg
mouse were crushed and cell suspensions were cultured in T-cell medium (45% RPMI1640, 45% DMEM, 10% FBS, 1% Penicillin-Streptomycin, 1X 2-mercaptoethanol) with
0.5 μg/mL SIINFEKL and 10 ng/mL IL-2. After 2 days of culture, cell suspension was
supplemented with fresh medium, SIINFEKL and IL-2. On day of transfer, CD8+ T cells
were enriched from cell suspension using MACS LS column and Ly-2 microbeads
(Miltenyi) and suspended in ice-cold sterile 1X PBS. Enrichment was verified (every 5th
experiment) to be >90%. 5 million activated T cells were transferred into mice by retroorbital venous injection (i.v.) on days noted. T cell transfer was supplemented with five
rIL-2 injections (20,000 IU per mouse, i.p.) every other day for 10 days.
DC-modulatory therapy and radiation therapy
Mice received 30 μg of Flt3L (CDX-301, Celldex) i.p. every day for 9 days as previously
published (Salmon et al., 2016). Mice received 100 μg of anti-CD40 (clone FGK4.5,
BioXCell) i.p. every 5 days starting concurrent with other treatment upon palpation and
1st ultrasound measure. Certain mice received 25 μg of STING agonist (ML-RR-S2
CDA, MedChemExpress) intratumorally every 4 days starting concurrent with other
treatment upon palpation and 1st ultrasound measure.
Mice received radiation (RT) as three daily fractionated doses (8 Gy x 3) using the
Small Animal Radiation Research Platform (SARRP200, XStrahl Life Sciences). Mice
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were injected i.p. with an iodine contrast agent (2100 mg/kg) before being placed on the
irradiation platform one at a time under isoflurane anesthesia. Conebeam computed
tomography (CT) imaging was performed for each individual mouse to pinpoint the
pancreas, images were imported into Muriplan and used to select an isocenter. The
tumor was then irradiated using anterior-posterior-opposed beams using the 10mm x
10mm collimator at a dose rate of 3.9 Gy/min. Mice were monitored over 2 weeks for
signs of radiation sickness or weight-loss.
Cytotoxicity and degranulation assays
KPC-derived cells were cultured in 96-well format with purified, activated OT-I CD8+ T
cells (derived and expanded as described above) in triplicates at different ratios.
Positive-control wells contained OT-I cells incubated with CD3/CD28 dynabeads
(Ebioscience). Cytotoxicity was measured using CyQUANT LDH release assay (Thermo
Fisher) run according to kit instructions on the Synergy H1 microplate reader (Biotek).
Viability of tumor cells was also measured using PrestoBlue HS fluorescent reagent
(Thermo Fisher) according to manufacturer’s instructions. OG cell killing was verified by
measuring GFP fluorescence levels normalized to cellular density on the Synergy H1
microplate reader. To measure CD107a degranulation, parallel wells containing tumor
and T cells were co-incubated with 1 μM Monensin (Biolegend) for 5 hours at 37C and
5%CO2. CD107a antibody was utilized in the incubation step, prior to flow cytometric
labeling.
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Bone marrow chimerism
Recipient mice received two (split) doses of 450 cGy four hours apart, followed by
transplant of bone marrow by retro-orbital injection (i.v). Irradiation was carried out using
an X-ray irradiator (XRAD 320). Donor bone marrow was prepared as follows: donor
mice were sacrificed by CO2 inhalation, both femurs were extracted in sterile setting and
flushed using pulsed centrifugation to collect marrow. Bone marrow was reconstituted in
cold sterile serum-free 1X HBSS and injected i.v. at a concentration of 5 million cells per
100 μL per mouse. Mice were monitored over 2 weeks for signs of radiation sickness or
weight-loss.
Vaccination strategy
PC-OG mice received 40 μg of full-length Ovalbumin (Invivogen) and 25 μg of HMW
PolyI:C adjuvant (Invivogen) in Cultrex subcutaneously on day 0, followed by analysis at
day 10 and day 20. Vaccination was verified by measuring OVA-specific T cells in blood
and draining lymph nodes using dextramer immunolabeling.
Immunohistochemical staining
Tissues were fixed in 10% neutral-formalin for 18 hours, embedded in paraffin after
graded-ethanol dehydration, and sectioned into 6-μm sections using a microtome.
Where applicable, FFPE sections were stained for Hematoxylin & Eosin (Thermo
Fisher), Picro-Sirius Red (Sigma-Aldrich) and Masson’s Trichrome (Diagnostic
Biosystems) according to manufacturer’s instructions. Automated staining of tissues
was carried out on the Bond Rxm (Leica Biosystems) following dewaxing and
appropriate epitope retrieval. Immunostaining was chromogenically visualized using the
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Bond Polymer Refine Detection alone or in conjunction with Bond Intense R Detection
Systems (DS9263, Leica Biosystems). Staining used antibodies listed in Table 2.3.
Slides were mounted using Xylene-based Cytoseal (Thermo Fisher) or Vectamount
(Vector Labs) as appropriate.
Immunofluorescence staining
6 μm-thick cryo-sections were air-dried and fixed in 4% PFA (Ted Pella, Inc.) for 20
mins before being washed thrice with PBS. Slides were peroxidase-quenched by
incubating in hydrogen peroxide (1% v/v in PBS, Invitrogen) for 10 min at RT. After
blocking for 30 mins at RT in blocking buffer (5% goat serum, 2.5% BSA in 1X PBS),
slides were additionally blocked using an Avidin/Biotin Blocking Kit (Vector Labs)
according to manufacturer’s recommendations. Slides were then incubated overnight in
a humidified chamber at 4 °C with antibodies listed in Table 2.3. The next day, slides
underwent three PBST (1X PBS with 0.05% Tween-20) washes, and incubation with
anti-rat HRP (1:500) for 30 mins at RT. After three more PBST washes, slides were
incubated in biotinylated Tyramide reagent (1:50) for 8 mins, followed by washes and
AlexaFluor 594-conjugated goat streptavidin secondary antibodies (Invitrogen) for 30
mins at RT. Slides were subsequently washed and mounted using Vectashield with
DAPI (Vector Labs). Automated staining of FFPE tissues was carried out on the Bond
Rxm (Leica Biosystems) following dewaxing and EDTA-based epitope retrieval
(AR9640, Leica Biosystems). Fluorescence immunostaining for GFP and CK19 was
visualized on an Open Research Kit arm using standard (non-TSA) immunostaining
protocols.
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Multiparametric flow cytometry
Following tissue digestion, single cell suspensions were resuspended in flow cytometry
buffer (PBS containing 1% BSA and 5 mM EDTA), FcR blocked with rat anti-mouse
CD16/CD32 antibodies (EBioscience) for 10 minutes and pelleted by centrifugation.
When used, Live/Dead viability dyes were applied for 15–30 min at room temperature
prior. Where applicable, CD8+ T cells specific for antigen OVA were labeled by
incubating cell suspension with H2Kb::SIINFEKL-specific MHCI dextramer (1:5;
Immudex protocol) for 10 mins at room temperature prior to extracellular staining. Cells
were consequently labeled with 100 μl of fluorophore-conjugated anti-mouse
extracellular antibodies at recommended dilutions for 25 mins on ice. Intracellular
staining for transcription factors and intracellular markers was conducted subsequently
using the EBioscience Transcription Factor Staining buffer set, according to
manufacturer’s instructions. All antibodies are listed in Table 2.3. FCS Data were
acquired on BD LSR-II and BD Fortessa X-20 (BD Biosciences) within 3-4 days, and
analyzed using FlowJo software (v10) with application of bead-based post-hoc
compensation. For live analysis of GFP or ZsGreen uptake, fixation step was not
performed, and labeled cells were analyzed immediately (within 2 hours) on
cytometer(s).
For experiments that measured T cell cytokines involving ex vivo stimulation,
primary cell suspensions were incubated in 96-well format with 1 μM Brefeldin A
(Biolegend) and 1X Stimulation Cocktail (Ebioscience) for 4 hours at 37C and 5%CO2.
Post-incubation, cells were quenched and resuspended in Fc block buffer and then
labeled with fluorophore-conjugated anti-mouse antibodies as above.
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Mass cytometry
Human tumor samples were digested in HBSS supplemented with 2mg/ml collagenase
A (Roche), 2.5U/ml hyaluronidase and DNase I at 37C for 30 mins with agitation to
generate single-cell suspensions. Cell suspensions were counted and stained in 5 μM
cisplatin per million cells for exactly 3 mins on ice and washed with Cy-FACS buffer
(PBS, 0.1% BSA, 0.02% NaN3, 2mM EDTA) twice. Cells were incubated with FcR
blocking reagent plus surface-antibody cocktail for 40 mins on ice. After incubation,
surface-marker stained cells were washed twice with Cy-FACS buffer. Cells were then
fixed with 4% PFA for 10 mins on ice and permeabilized with permeabilization buffer
(Invitrogen) for 40 mins containing the intracellular stain cocktail. All antibodies are
listed in Table 2.3. Cells were then washed twice with PBS and stained with 200 µl of
DNA intercalator per million cells. Cells were acquired on a CyTOF2 mass cytometer
(Fluidigm) and data were uploaded to Cytobank for further analysis. Events were gated
on singlets, live, and CD45+. A maximum of 100,000 events were then visualized into
two dimensions using standard t-SNE algorithm. Populations of interest were manually
gated and verified based on lineage marker-expression.
ELISA
Blood was collected by cardiac puncture at endpoints and serum isolated by
coagulation and centrifugation. Serum aliquots were snap-frozen at -80C until use. Total
IgG1 was measured using IgG (Total) Mouse ELISA Kit (Thermo) and OVA-specific
IgG1 was measured using Anti-Ovalbumin IgG1 (mouse) ELISA Kit (Cayman Chemical)
on duplicate sera samples diluted 1:10,000 and 1:100 respectively. Absorbance values
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within dynamic range were read at 450 nm and 570 nm, and final concentrations were
interpolated on Sigmoidal (4PL) fit of standard-curve.
DC cross-presentation assay
Endstage pancreatic and lung GEMM tumors were harvested on the same day as
detailed above. Following tissue digestion, single cell suspensions were resuspended in
flow cytometry buffer at required cell concentration, FcR blocked with rat anti-mouse
CD16/CD32 antibodies (EBioscience) for 10 minutes and pelleted by centrifugation. 20
million cells were consequently labeled with 1000 μl of fluorophore-conjugated antimouse extracellular antibodies for 25 mins on ice. Subsequently, cells were incubated
with 7-AAD for live/dead discrimination and run live on BD FACSAria-II (BD
Biosciences) using a 100 μm nozzle and low flow rate.
After excluding T, B cells, granulocytic & monocytic cells, around 2000–5000
MHCIIhiCD11chiCD24hiXCR1+ cDC1s and MHCIIhiCD11chiCD11b+ cDC2s were sorted
into complete media (containing Flt3L, L-Glutamine, beta-mercaptoethanol and NEAA)
and plated in 384 well-plate format. cDC1 and cDC2 wells were incubated with 2 μg/ml
SIINFEKL [OVA257-264] and ISQ [OVA323-339] peptide, respectively, for 3 hours at 37C
prior to 2 washes. Freshly isolated naïve splenocytes from OT-I and OT-II mice were
enriched for CD8+ T cells and CD4+ T cells, respectively. OT-I and OT-II cells were
labeled with CellTrace dye as well as Fluo4-AM Calcium indicator (Thermo) according
to kit instructions, and subsequently co-cultured with cDC1s and cDC2s at 5:1 ratio.
Cellular trafficking and calcium flux were longitudinally tracked over 3 hours on Cytation
5 multi-reader (Biotek) and data normalized to T-cell alone wells.
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After 6 hours, CD8+ or CD4+ T cells from the above co-culture setup were lifted and
separately assayed on mouse IFN-g single-color ELISPOT strip according to
manufacturer’s instructions. Readings were taken on Immunospot S6 Universal
Analyzer (CTL) after 18 hours of incubation.
Western immunoblot
Tissue or cell lysates were harvested using radioimmunoprecipitation assay (RIPA) lysis
buffer [25 mM Tris-HCl pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% DOC, 0.1% SDS]
supplemented with protease and phosphatase inhibitors (Roche). Cell lysates were
resolved in Tris-glycine sodium dodecyl sulfate/polyacrylamide gel electrophoresis
(SDS/PAGE) gels and transferred to polyvinylidene difluoride (PVDF) membranes
(Invitrogen). After blocking in 1X TBST buffer with 5% w/v BSA, membranes were
probed with primary antibodies against Ovalbumin (PA1-196), GFP (D5.1) and betaactin (13E5) overnight at 4°C. Membranes were washed thrice in 1X TBST and probed
with HRP-conjugated secondary antibody for 1 hour at RT. Membranes were developed
with Pierce ECL Western Blotting Substrates and detected using a ChemiDoc XRS+
system (Bio-Rad).
RNA isolation
Total RNA was extracted from cryo-preserved pancreatic tissues using an E.Z.N.A.®
Total RNA kit (OMEGA) according to manufacturer’s instructions, and banked in -80C
until use. cDNA for downstream applications were synthesized using qScript cDNA
SuperMix kit (QuantaBio) according to manufacturer’s instructions.
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RNA sequencing and analysis
Samples were prepared in-lab according to kit manufacturer’s protocol, ribo-depleted
using RiboZero protocol and subsequently indexed, pooled, and sequenced on HiSeq
3000 (Illumina) at the Genome Technology Access Center (GTAC), Washington
University. Differential expression analysis of normalized counts (after standard
basecalling and demultiplexing) was performed to analyze for differences between
conditions and the results were filtered for only those genes with Benjamini-Hochberg
FDR adjusted p-values ≤ 0.05. For each contrast extracted with Limma, global
perturbations in known Gene Ontology (GO) terms and KEGG pathways were detected
using the R/Bioconductor package GAGE to test for changes in expression of the
reported log2 fold-changes reported for each term versus the background log2 foldchanges of all genes found outside the respective term.
TCGA Patient Analysis
Gene expression data was downloaded for lung adenocarcinoma (TCGA, Nature 2014)
and pancreatic adenocarcinoma (TCGA, PanCancer Atlas) from cBioportal. Comparison
of DC1 gene signature (KIT, CCR7, BATF3, FLT3, ZBTB46, IRF8, BTLA, MYCL,
CLEC9A, XCR1) between LUAD and PAAD was conducted using ssGSEA on the
GenePattern web interface from the Broad Institute. Expression scores were Z-score
normalized on GraphPad Prism v8.
Image analysis
Whole-tissue scans at 10X or 20X magnification were obtained on a Zeiss Axio Scan Z1
brightfield/fluorescence Slide Scanner. Additional 40X images were taken when
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necessary on the Nikon Eclipse 80i brightfield/epifluorescence microscope (Nikon).
Whole-tissue scans were analyzed with HALO software (Indica Labs) using Area
quantification V1.0, Cytonuclear v1.5, Cytonuclear FL v1.4 module or Immune Cell
Proximity v1.2 module. Where noted, grading was conducted by a trained pathologist in
a blinded fashion and verified by principal investigator post-hoc. For proximity analyses,
distances less than or equal to zero were culled for clarity. The normalized percentage
of target cells (T cells, cDCs) proximal to CK19-expressing tumor lesions was binned
and quantified on GraphPad Prism v8.
Statistical analysis
All statistical analyses were performed using GraphPad Prism software v8, with final
input from a Biostatistics core expert at Washington University. All data are
representative of at least two independent experiments, unless specifically noted.
Sample size was pre-calculated to satisfy power-requirements (with >85% confidence)
in most experiments, and is specified in the figure legends wherever applicable. To
accomplish randomization for KI experiments, animals were sorted by a blinded
investigator with tumor sizes in ascending order and then groups were assigned in
descending order. Each group was checked post-hoc to verify no statistical difference in
average starting tumor size. Randomization was not possible for genetic mouse studies
except where mice were randomized at ultrasound-guided enrollment stage. Data are
shown as mean ± s.e.m., unless otherwise noted. Normal-distribution of data was
assessed using the D’Agostino–Pearson omnibus normality test in Prism. Statistical
tests such as unpaired parametric Student’s t-test, ANOVA analysis (Bonferroni multiple
comparison) or unpaired non-parametric Mann–Whitney U test were used appropriately
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based on normality of data. For survival analyses, Log-Rank (Mantel-Cox) test was
used. For proximity analyses; the non-parametric Kolmogorov-Smirnov test was used to
distinguish differences in frequency distributions. p < 0.05 was considered statistically
significant for all studies. *p < 0.05; **p < 0.01; n.s. denotes not significant.

Data and software availability
Raw bulk-RNA sequencing data from KPC or KPC-OG pancreatic lesions can be found
at the Gene Expression Omnibus Repository (GEO) accession number GSE131602. All
software packages used are publicly available through commercial vendors.
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Chapter 3: Conclusions and Future
directions
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3.1 Conclusions
In lieu of analyses of human tissues, spontaneous mouse models are invaluable
for defining how immune surveillance gradually becomes ineffective as tumors
progress. In the unperturbed model of PDAC detailed above, strong antigenicity is
insufficient to drive T cell-dependent tumor control and does not elicit immune-editing.
This is in contrast to recent work in transplant models (Evans et al., 2016) and
underscores how different immune outcomes can be, depending on initial inflammatory
context. There is a marked influx of inflammatory myeloid cells at early PANIN stages,
which is characteristic of this disease model (Bayne et al., 2012; Clark et al., 2007).
However, distinct antigen-specific T and B cell responses can be identified after tumor
initiation, suggesting that antigenic PDAC lesions do not grow immune-privileged, in
agreement with previous observations in the KPC model and human patients (Bailey et
al., 2016a; Pillarisetty, 2014; Stromnes et al., 2015).
Our studies indicate that antigenicity may be recognized distinctly in the
pancreatic microenvironment. It is plausible that internal organs such as the pancreas
are programmed to respond to pathogenic or neoplastic cues in a tolerogenic manner
when compared to mucosal barrier organs such as the lung (Salmon et al., 2019).
Frequent environmental insults, foreign antigens, and mitogens in the lung entrain a
rapid response to antigenic lesions in the airway epithelia (Lelkes et al., 2014), and the
lung-draining lymphatics are amenable for efficient T cell priming (Cook and Bottomly,
2007). In contrast, the pancreas and its lymphatic drainage may not designed to be at
this heightened state of surveillance, which might reduce effective T cell immunity
against antigenic lesions and thus allow the ‘fibro-inflammatory program’ to dominate.
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Additionally, local microbial communities and dysbiosis can influence immune
responses to tumor antigens very differently in organs such as the lung or skin when
compared to the hepatobiliary/pancreatic tract, wherein the commensal gut-proximal
population is anatomically divergent (Jin et al., 2019; Routy et al., 2018). Of note, it has
been shown that pattern recognition receptor activation on myeloid cells in response to
microbial patterns (PAMPs) or sterile inflammation can accelerate PDAC progression
(Pushalkar et al., 2018; Seifert et al., 2016). All of these might factor into the organspecific differences observed. Overall, our comparative studies suggest that anti-tumor
surveillance in PDAC is heavily influenced by the ‘hard-wired’ program of the anatomical
contexture.
The enrichment of TH2 and TH17 CD4+ T cells observed in early KPC-OG
pancreata is likely causal to the accelerated tumor progression observed. These cell
types and their associated cytokines have been separately implicated in tumorpromoting inflammation, fibrosis, neovascularization and recruitment of inflammatory
myeloid cells (Grivennikov et al., 2012; McAllister et al., 2014; Ochi et al., 2012).
Indeed, we observe a correlation between myeloid cell infiltration and mitogenic tumor
cell activation, echoing work from other groups (Liou et al., 2013; Zhang et al., 2014;
Zhang et al., 2017b). Our observations suggest an interplay between these pathogenic
immune compartments; immune-cell derived TNF-a and IL-17A have been shown to
drive mitogenic effects and aggressiveness in PDAC and other tumors through
alternative p38 MAP kinase activation (Alam et al., 2015), potentially via downstream
NFκ-B signaling (Charles et al., 2009; De Simone et al., 2015; Egberts et al., 2008).
TH17 cells have been associated with mixed prognosis across several tumors (Bailey et
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al., 2014), but TH2 immune infiltrates have been linked to worse outcomes in PDAC
patients (Bellone et al., 1999; De Monte et al., 2011; De Monte et al., 2016; Fukunaga
et al., 2004). Although we did not observe this in our model, concurrent work from other
groups has shown regulatory T cells also play an important role in acceleration of
pancreatic tumorigenesis.
Using spontaneous models, we observed that cDC paucity in the pancreas and
their exclusion from growing lesions are linked to the weak or aberrant T cell response
against tumor neoantigenicity. Human PDAC patients have been reported to have low
numbers of DCs that become rarer with tumor progression (Dallal et al., 2002; Hiraoka
et al., 2011), and our study re-affirms this marginalization. cDC mobilization via Flt3L at
pre-PANIN stages reduced TH2/TH17 activity in the pancreas and delayed progression
of antigenic lesions, supporting a protective role at this stage (Bedrosian et al., 2011;
Henning et al., 2013). The influx of cDCs in our study was associated with concomitant
reduction in collagen-deposition, which might further benefit cDC activity by enabling
tumor antigen sampling, better antigen presentation, and trafficking to dLNs (Hugues,
2010). Importantly, these observations suggest that the PDAC microenvironment retains
its capacity for TH1 and CTL activity, and a lack of sufficient cDCs simply precludes
effective anti-tumor immunity.
CD11b+ TAMs/DCs that skew immunity towards TH2 responses have been
described in the PDAC TME (Ochi et al., 2012) and secondary metastases (Kenkel et
al., 2017). Tumor-permissive roles for CD11b+ DCs via FOXP3+ TREGs or FOXP3neg
regulatory TR1 cells have also been recently reported (Barilla et al., 2019; Jang et al.,
2017). Recently, transcriptional analyses of mouse and human cancer revealed cDC2
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subsets driven by distinct transcriptional regulators, with a pro-inflammatory subset
eliciting TH17 responses (Brown et al., 2019). Although we see a similar TH17 induction
in KPC-OG pancreatic lesions, this is without enrichment of TR1 signatures or TREGS.
This could be due to the fact that our studies were restricted to spontaneous PDAC
models and therefore elicited different regulatory networks from transplant models. It is
important to emphasize that DC2s are heterogeneous and can have tumor-suppressive
roles based on the inflammatory context (Binnewies et al., 2019; Brown et al., 2019;
Laoui et al., 2016). Hence, it is likely that the malleable CD11b+ DCs in the PDAC TME
can be programmed to benefit TH1 immunity, and Flt3L-treatment might help achieve
this.
Clinical trials in the past involving Flt3L monotherapy have been underwhelming
due to the lack of appropriate DC activation and licensing (Freedman et al., 2003;
Morse et al., 2000). The paradigm has now shifted to include strategies for enhancing
DC function in the TME. For example, trials are now underway in lymphoma, squamous
cell carcinoma and non-small cell lung cancer utilizing Flt3L-based vaccination
(NCT03789097, NCT02839265). Combination treatment involving anti-CD40 and Flt3L
in our study caused a dramatic increase in tumoral cDCs and CD8+ T cells, despite preDC mobilization from bone marrow being similar compared to Flt3L-monotherapy. This
could be due to enhanced DC survival in situ, as signaling downstream of RANK and
non-canonical NF-kB signaling upon CD40 ligation is known to enhance DC survival
(Hou and Van Parijs, 2004; Miga et al., 2001; Ouaaz et al., 2002). Flt3L and CD40
agonism have been shown independently to enhance IFN-g and IL-12 production
(Borges et al., 1999; Chaudhry et al., 2006; Garris et al., 2018), and their combined
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activity could potentially impose TH1 immunity in the otherwise-suppressive PDAC TME
and drive better CTL survival and activity. This therapeutic strategy is promising and is
now being tested in a Phase I trial involving advanced malignancies (NCT03329950). It
is important to note that even though CD40 agonism has been shown to rely on Batf3dependent DCs in PDAC (Byrne and Vonderheide, 2016) it is also known to be
mediated by TAMs in other contexts (Hoves et al., 2018; Stromnes et al., 2019).
Multiple myeloid cell types could be mediating CD40-dependent immunity in the PDAC
TME; this redundancy could be of benefit to patients with extremely low numbers of
cDCs.
Localized RT in the TME can induce immunogenic cell death, heighten damageassociated molecular pattern (DAMPs) or alarmin production, and generate tumorassociated antigens; thus increasing the chance of productive T cell priming (Ngwa et
al., 2018). In our study, immunogenic RT after Flt3L-mobilization and prior to CD40stimulation resulted in superior tumor control when compared to RT alone. Going
forward, it becomes important to experimentally determine the best treatment-window to
administer RT, so as to maximize priming capacity in recently mobilized cDCs while
maintaining their T cell-assistive function in the tumor. It might also be germane to
combine this treatment with other agonistic pathways such as OX40 or 41BB, to
exponentially benefit T cell co-stimulation. Meaningful interventions in PDAC will likely
necessitate similar combinatorial strategies (Baird et al., 2016; Hammerich et al., 2019a;
Rech et al., 2018).
The therapeutic strategy described here focuses on modulating cDCs and does
not target CTLs in the TME that might already be exhausted. This may have the added
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benefit of altering the PDAC microenvironment for fully-integrated immune killing. As an
example, the increase in intratumoral NK and NKT cells upon Flt3L treatment can have
a profound effect on sustaining DC-T cell interaction; NK cells have been implicated in
attracting cDCs to tumor microenvironment and sustaining CTL infiltration (Barry et al.,
2018; Bottcher et al., 2018), and NKT cells can substitute for TH1 help in providing
necessary licensing for IL-12 production by DCs (Nair and Dhodapkar, 2017). Another
facet is the reduction in fibrosis and myofibroblast infiltration observed upon CD40
agonist plus Flt3L treatment. Studies in PDAC mouse models have shown that stromal
remodeling and resolution of fibrosis can facilitate drug delivery and enhance CTL
activity in the TME (Feig et al., 2013; Jiang et al., 2016; Stromnes et al., 2015). Notably,
CD40 agonism has been previously shown to reduce pathogenic fibrosis by enhancing
matrix remodeling properties of tumor-infiltrating monocytes (Long et al., 2016). The
marked reduction in fibrosis observed upon CD40 agonist plus Flt3L treatment augurs
well for combinatorial strategies that can further unleash CTL activity in the TME.
Stromal remodeling has a positive feedback effect on cDC migration, antigen sampling,
and activity (Boissonnas et al., 2013; Hope et al., 2017); this can be advantageous for
sustaining DCs in similarly ‘insulated’ solid tumors.
In conclusion, cDCs are critical to T cell-mediated immune restraint of PDAC, but
are especially scarce and dysfunctional in the pancreatic TME (Figure 3.1). Increasing
the numbers and activity of cDCs in PDAC is a distinctive therapeutic strategy that may
improve either standard-of-care or immune-based therapies that currently struggle to
control this disease.
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3.2 Open Questions and Future Directions
My work on tumor immunity in pancreatic cancer lays the foundation for several
questions worth pursuing:

How does evolutionary immune response to microbiome influence
adaptive responses, especially in PDAC?
It is now fairly well appreciated that microbiome (and mycobiome) dysbiosis have
tremendous impact on most tumor progression (Helmink et al., 2019), including PDAC.
Studies are now determining how such dysbiosis can influence innate immune cells and
aggravate immunosuppression in the TME (Sethi et al., 2019). Another facet would be
to understand how co-evolution of organs such as the bowel/pancreas/liver with
commensal microbiota has shaped the immune responses in these organs. Of note,
elegant work recently has shown that the GI tract proximal to pancreas/liver are
immunologically wired to generate a tolerogenic response (Esterhazy et al., 2019). It is
hence conceivable that in situ DCs and other antigen presenting cells in steady–state
pancreata are educated by developmental programs to generate ‘default’ Th2 and Th17
responses that sabotage anti-tumor responses. Ex vivo stimulation experiments
comparing DC responses across different tumor models and classical pathogeninfected mice (e.g.- helminth) would be a good starting point to dissect the plasticity of
these developmental programs.
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Along similar lines, our findings raise the possibility that certain indolent
anatomical sites such as the pancreas are disadvantaged when it comes to anti-tumor T
cell immunity due to their low cDC distribution. Does this mean adaptive immunity in
DC-replete tissues (i.e. those having “enough” cDCs patrolling) will not benefit from DCcentric therapeutic approaches? Such questions can be addressed by comparing
efficacy of Flt3L-CD40 treatment in multiple tumor GEMMs and by genetically
manipulating DC function in these settings.

Is cDC density and function correlated with PDAC patient outcomes
to immunotherapy?
This question primarily arises based on observations that a paucity of cDCs in
mouse models and PDAC patients was correlated with low T cell activity, and that
enhancing their number and function in the TME resulted in activated T cell infiltration
and tumor control. It might hence be beneficial to measure tumoral cDC density and
functional markers as a surrogate for T cell therapy ‘responsiveness’, possibly at a
resection stage. Indeed, measuring cDC precursors in peripheral blood could also serve
as a proxy, and allow easier pre– and post–treatment analyses. Indeed, several studies
have shown cDC1 presence to correlate with better overall survival and outcomes
across melanoma, head and neck cancer, breast cancer and lung cancer (Bottcher and
Reis, 2018; Cancel et al., 2019). However, progress towards a ‘DC-immunoscore’ has
been curtailed by the lack of robust and standardized markers of cDC subsets in human
tissue. Techniques such as multiplexed imaging, mass cytometry, single-cell
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sequencing techniques and multiplexed ion-beam imaging have started to provide us a
better picture of patient tumor immune heterogeneity, and can help create a harmonized
system for such correlation studies in PDAC. Instead of solely focusing on T cells,
stratifying this disease on the basis of cDC/myeloid biology can be especially helpful to
prioritize immunotherapy for patients who are most likely to benefit.

How

diverse

and

divergent

are

DC

subsets

in

pancreatic

tumorigenesis and progression?
Our current study did not delve deep into the heterogeneity of cDC responses,
and whether certain subtypes dominate over tumor progression. Indeed, several recent
studies have expanded our understanding of tumoral DC/myeloid heterogeneity
(Binnewies et al., 2019; Brown et al., 2019; Lavin et al., 2017; Villani et al., 2017;
Zilionis et al., 2019). Several groups, including ours, are currently carrying out singlecell level analyses of PDAC immune populations across stages, and comparing the
myeloid subsets with publicly available datasets, to generate an atlas of DC fates in this
disease. Additionally, it would also be germane to study the dynamics of monocytederived DCs in this disease; they are substantial in the inflamed TME of PDAC and can
be elicited by similar Flt3-based mechanisms. How monocytic DCs impact cDC and/or
anti-tumor T cell responses are worth investigating, especially as they have been shown
to be immunosuppressive and engage regulatory T cells in certain contexts (Kenkel et
al., 2017). Newer tools such as the Snx22 and Ms4a3 reporter mice that differentiate
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conventional DCs from inflammation-induced monocytic lineages will enable such
studies (Brahler et al., 2018; Liu et al., 2019).

What is the mechanism by which anti-CD40 and Flt3L drives
synergistic cDC infiltration into PDAC?
Our observation that administering anti-CD40 and Flt3L resulted in dramatic DC1
infiltration into the hard-to-penetrate PDAC TME raises further questions about the
mechanisms at play. There are 3 broad possibilities for this phenomenon – (1)
increased differentiation and mobilization from bone marrow precursors resulting in
systemic increases and passive influx into the tumor, (2) targeted migration and
retention of cDCs in the inflamed TME, and (3) increased survival signals for cDCs in
the TME. cDCs are known to be short-lived and terminally differentiated cells in nonlymphoid tissue (Ginhoux et al., 2009), hence one would not expect increased numbers
due to proliferation at the tumor site.
It is most likely that the observations are due to increased migration of DC
precursors homing to the tumor site. It is possible that CD40 ligation physically
reshapes the fibrotic landscape and ‘reformats’ the TME to elicit DC chemoattractants
such as CCL4, CCL5 and XCL1, potentiating the initial mobilization by Flt3L. This has
indeed borne out in some preliminary data from our group (unpublished). Although the
source of these chemoattractants is not pinned down, it is likely to be newly-licensed
DCs and NK cells (Bottcher et al., 2018) which incidentally are enriched in dual-treated
tumors. It is also possible that cDCs upon CD40 and Flt3L treatment are exposed to
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survival cues, metabolic changes and epigenetic modifications that enable them to
function ‘longer’ in the TME. Notably, CD40 ligation has been demonstrated to induce
the expression of the pro-survival factors Bcl2 and Bcl-xL in DCs, support RANKL
signaling and sensitize them to PTEN-mTORC1 signaling (Ma and Clark, 2009);
whether such pathways are at play in infiltrative tumoral cDCs is worth scrutinizing.
It is noteworthy that CD40 ligation can act through activating B cells and
monocytic/macrophage subsets in the PDAC TME; this has been shown previously
(Beatty et al., 2015; Long et al., 2016) and is likely occurring in our treatment strategy.
Depletion of these cell types in the context of therapy will clarify whether they are
dispensable to treatment outcome or if they have a detrimental impact. In summary, one
could envision this treatment approach is generating a ‘DC-permissive’ TME, and
understanding how this happens can help us develop similar/better strategies.

How does boosting cDCs augment T cell activity in PDAC?
We noticed that Flt3L treatment alone does not result in T cell infiltration either at
early stages of disease or once PDAC has set in. The combinatorial effect observed
upon anti-CD40 treatment suggests special benefit to T cell biology in this disease, and
this is worth pursuing. Similar to possibilities with DCs, we might be eliciting one or
several of the following possibilities – (1) increased efflux of activated T cells from
surrounding lymphoid organs and T cell chemoattraction to inflamed TME, (2) increased
priming of naïve T cells in draining lymph nodes resulting in larger pools of antigenspecific T cells, and (3) enhanced proliferation/survival/persistence of T cells in the TME
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due to environmental cues and metabolic changes. Preliminary data from our group
suggest T cell-recruitment chemokines such as CXCL9 and CXCL10 are increased
dramatically in anti-CD40 plus Flt3L treated tumors. Along these lines, we can ascertain
the importance of ‘recruitment’ by blocking T cell egress (genetic or pharmacological)
and studying efficacy of treatment.

What is the quality and fate of T cell immunity resulting from cDCdirected therapy in PDAC?
The characteristics of these infiltrating T lymphocytes is a big gap in our current
understanding of Flt3L-CD40 therapy, and an area of active research in our group.
Experiments utilizing mass cytometry suggest the DC-targeted therapy magnifies
superior Tbet+ CD4+ TH1 cells, dramatically enhances Granzyme B-producing CTLs but
also expands PD1+CTLA4+TIM3+CD39+ exhausted CTLs (unpublished). This provides
rationale for combining anti-PD1 and anti-CTLA4 immunotherapy with Flt3L-CD40
therapy, currently being pursued.
Future experiments will also interrogate these T cell populations with more
granularity, to understand if we are simply expanding a pre-existing pool, modifying
certain T cell subsets or bringing in new T cells. Importantly with our antigenic OG
model, we can also test if the enhanced T cell response in PDAC is oligoclonal (directed
towards a few key antigens) or polyclonal (more antigen agnostic) as this would inform
us of their efficacy in human tumors that are more heterogenous. We can leverage new
technologies such as single-cell RNA sequencing and TCR sequencing to map clonality
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of these treatment-responsive T cells, and also study their transitions (e.g.- from naïve
to terminally exhausted or transiently exhausted) using diffusion maps and pseudo-time
analyses (Yost et al., 2019).

Can we tailor cDC-targeted strategies to further efficacy of current
therapies at metastatic sites ?
A major advantage of immunotherapies including our strategy is their systemic
influence and potential for abscopal efficacy driven by antigen-specific T cells. This
becomes more imperative when we consider the majority of deaths due to metastatic
PDAC and other metastatic tumors. Pancreatic tumors metastasize often to the liver
and lung, educating the foreign microenvironment to mimic the dense fibro-inflammation
observed at the primary site (Lee et al., 2019; Nielsen et al., 2016) and theoretically also
influencing cDC–T cell surveillance. I believe it would be extremely useful to study the
impact of Flt3L-CD40 therapy on metastases, and additionally test its efficacy in
conjunction with immunotherapy. Understanding how the metastatic environment
mimics or differs from primary site would also allow us to customize approaches and
boost cDC effectiveness appropriately (e.g.- use TLR3 or TLR9 agonists in place of
anti-CD40). I hope we can build on this understanding of cDC biology, unleash better T
cell immunity and improve the effectiveness of therapies currently struggling to control
metastatic spread.
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3.3 Figures
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Figure 3.1 – Summary of dissertation findings
We demonstrate that T cell immune surveillance of pancreatic cancer is
divergent from immunity in lung adenocarcinoma (or sarcoma). Early lesions in
antigenic spontaneous models of PDAC fail to elicit effective TH1 and antigen-specific
CD8+ CTL responses, and instead favor the expansion of tumor-promoting TH17
responses. This is in contrast to similarly modeled lung cancer. We identify one of the
fundamental reasons for aberrant neoantigen-directed responses in pancreatic lesions
to be the paucity of conventional dendritic cells, specifically cDC1s. The relatively
scarce cDCs in the pancreatic lesions are excluded from tumor parenchyma, and their
antigen trafficking and presentation functions are disrupted. Increasing cDC surveillance
using Flt3L in early PDAC can result in restoration of CD8+ T cell activity and
suppression of TH17 fibro-inflammation.
From a therapeutic standpoint, enhancing cDC mobilization (using Flt3L) and
function (using anti-CD40 agonist) in established PDAC can prompt efficient antigen
trafficking to dLN, license tumoral cDCs to function as better antigen presenters,
enhance T cell infiltration, and generate holistic tumor–controlling immunity. Anti-CD40
treatment can also elicit broader activity in the TME to initiate matrix remodeling and
reprogram other myeloid cells. We demonstrate the utility of such DC–targeted therapy
in augmenting radiation therapy and immunotherapy.
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